<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Med</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Med</journal-id><journal-id journal-id-type="publisher-id">jcm</journal-id><journal-title-group><journal-title>Journal of Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2077-0383</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7463888</article-id><article-id pub-id-type="doi">10.3390/jcm9082441</article-id><article-id pub-id-type="publisher-id">jcm-09-02441</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>A Panel of Broad-Spectrum Antivirals in Topical Ophthalmic Medications from the Drug Repurposing Approach during and after the Coronavirus Disease 2019 Era</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7020-0823</contrib-id><name><surname>Napoli</surname><given-names>Pietro Emanuele</given-names></name><xref ref-type="aff" rid="af1-jcm-09-02441">1</xref><xref ref-type="aff" rid="af2-jcm-09-02441">2</xref><xref rid="c1-jcm-09-02441" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Mangoni</surname><given-names>Lorenzo</given-names></name><xref ref-type="aff" rid="af1-jcm-09-02441">1</xref></contrib><contrib contrib-type="author"><name><surname>Gentile</surname><given-names>Pietro</given-names></name><xref ref-type="aff" rid="af1-jcm-09-02441">1</xref></contrib><contrib contrib-type="author"><name><surname>Braghiroli</surname><given-names>Mirco</given-names></name><xref ref-type="aff" rid="af1-jcm-09-02441">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1520-7760</contrib-id><name><surname>Fossarello</surname><given-names>Maurizio</given-names></name><xref ref-type="aff" rid="af1-jcm-09-02441">1</xref><xref ref-type="aff" rid="af2-jcm-09-02441">2</xref></contrib></contrib-group><aff id="af1-jcm-09-02441"><label>1</label>Clinica Oculistica, San Giovanni di Dio Hospital, Azienda Ospedaliera Universitaria di Cagliari, 09124 Cagliari, Italy; <email>lollomangoni92@gmail.com</email> (L.M.); <email>gentilepietro92@gmail.com</email> (P.G.); <email>mirco.mbmb@gmail.com</email> (M.B.); <email>maurizio.fossarello@gmail.com</email> (M.F.)</aff><aff id="af2-jcm-09-02441"><label>2</label>Department of Surgical Sciences, Eye Clinic, University of Cagliari, 09124 Cagliari, Italy</aff><author-notes><corresp id="c1-jcm-09-02441"><label>*</label>Correspondence: <email>pietronapoli@ymail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>7</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2020</year></pub-date><volume>9</volume><issue>8</issue><elocation-id>2441</elocation-id><history><date date-type="received"><day>05</day><month>6</month><year>2020</year></date><date date-type="accepted"><day>27</day><month>7</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The coronavirus disease 2019 (COVID-19) represents a global concern of public health caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Its clinical manifestations are characterized by a heterogeneous group of symptoms and pictures (ranging from asymptomatic to lethal courses). The prevalence of conjunctivitis in patients with COVID-19 is at present controversial. Although it has been reported that only 0.9% developed signs of conjunctivitis, other report indicates that up to 31.6% of hospitalized patients had conjunctivitis. Considering the widespread use of topical ophthalmic medications (e.g., eye drops) by the general population, for various reasons (e.g., artificial tears, anti-glaucoma medications, topical antibiotics, etc.), the existence of their side effects as antiviral action should be investigated in-depth because it could possibly explain the aforementioned controversial data and represent a potential antiviral treatment for SARS-CoV-2 replication/diffusion on the ocular surface. Here, we discuss and elucidate the antiviral side effect of many eye drops and ophthalmic ointments commonly used for others purposes, thus showing that these secondary effects (not to be confused with the &#x02018;adverse effects&#x02019;) might be of primary importance in a number of viral infections (e.g., those for which there is no validated treatment protocol), according to a drug repurposing approach. Some active ingredients or excipients described here have activity against other types of viruses, thus suggesting potential broad-spectrum applications.</p></abstract><kwd-group><kwd>coronavirus disease 2019 (COVID-19)</kwd><kwd>coronavirus</kwd><kwd>severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</kwd><kwd>eye drop</kwd><kwd>therapy</kwd><kwd>treatment</kwd><kwd>antiviral</kwd><kwd>repurposing</kwd><kwd>drug</kwd><kwd>ocular surface</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-jcm-09-02441"><title>1. Introduction</title><p>The coronavirus disease 2019 (COVID-19) represents a global concern of public health that quickly spread around the world in early 2020 [<xref rid="B1-jcm-09-02441" ref-type="bibr">1</xref>,<xref rid="B2-jcm-09-02441" ref-type="bibr">2</xref>]. The origin of this disease is infectious, being caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and its clinical manifestations are characterized by a heterogeneous group of symptoms and pictures (ranging from asymptomatic to lethal courses).</p><p>Ocular involvement of COVID-19 and the potential role of the eye as a transmission route of SARS-CoV-2 have been previously described by several authors [<xref rid="B3-jcm-09-02441" ref-type="bibr">3</xref>]. Accordingly, the detection of specific cell-surface receptors on the ocular surface, called angiotensin converting enzyme 2 (ACE2), and proteins promoting the binding between the virus and the host cell, named transmembrane protease serine 2 (TMPRSS2), is of considerable importance for understanding the presence of SARS-CoV-2 at eye level [<xref rid="B3-jcm-09-02441" ref-type="bibr">3</xref>].</p><p>Apart from the problem of interpersonal transmission of COVID-19 through conjunctiva and the relative issues on the presence and replication of the virus at the level of human tears and ocular surface epithelia, the appearance of conjunctivitis in COVID-19 may be presumed to be not uncommon on the basis of inherent ocular tropism of other viral upper respiratory tract infections (adenovirus being the most common). Although the eyes are not the main transmission routes of SARS-CoV-2 [<xref rid="B4-jcm-09-02441" ref-type="bibr">4</xref>], conjunctivitis can be the first presenting symptom of COVID-19, before the appearance of other symptoms, such as cough and fever [<xref rid="B5-jcm-09-02441" ref-type="bibr">5</xref>,<xref rid="B6-jcm-09-02441" ref-type="bibr">6</xref>,<xref rid="B7-jcm-09-02441" ref-type="bibr">7</xref>].</p><p>The prevalence of conjunctivitis in patients with COVID-19 is, at present, controversial. Although it has been reported that only 0.9% of patients developed signs of conjunctivitis [<xref rid="B8-jcm-09-02441" ref-type="bibr">8</xref>], another report indicates that up to 31.6% (12 cases out of 32 patients) of hospitalized patients had conjunctivitis [<xref rid="B9-jcm-09-02441" ref-type="bibr">9</xref>].</p><p>Considering the widespread use of topical ophthalmic medications by the general population for various reasons (e.g., artificial tears, anti-glaucoma medications, topical antibiotics, etc.), the existence of side effects as an antiviral action should be investigated in-depth because it could possibly explain the aforementioned controversial data and represent a potential antiviral treatment for SARS-CoV-2 replication/diffusion on the ocular surface.</p><p>Here, we discuss and elucidate the antiviral side effect of many eye drops and ophthalmic ointments commonly used for others purposes, thus showing that these secondary effects (not to be confused with the &#x0201c;adverse effects&#x0201d;) might be of primary importance in a number of viral infections (in particular, those for which there is no validated treatment protocol), according to a drug repurposing approach.</p></sec><sec id="sec2-jcm-09-02441"><title>2. Drug Repurposing Approach: Potential Antiviral Action of Drugs in Eye Drops and Ophthalmic Ointments</title><p>An attractive alternative strategy of drug discovery is that of the drug repurposing approach, which eliminates the high costs and the time required for the <italic>de novo</italic> drug development. This is possible through the identification (sometimes accidental or fortunate) of some side effects (which are different from the adverse effects) of existing and available (approved) drugs. A famous example in ophthalmology is represented by bevacizumab (Avastin<sup>&#x000ae;</sup>, Roche, Genentech, South San Francisco, CA, USA) for wet age-related macular degeneration (original indication: colorectal cancer). Despite the fact that specific antivirals for SARS-CoV-2 are in development, the drug repurposing approach may suggest additional therapeutics for the ongoing pandemic.</p><p>For example, drugs that have demonstrated efficacy in vitro and in animal studies may be included in a panel of broad-spectrum antivirals for emerging viruses. This may be particularly useful in countries under emergency and for healthcare workers, for whom an extension of treatment options is very important during an epidemic.</p><p>Several researchers have identified and analyzed the antiviral activity of drugs found in various eye drops and ophthalmic ointments, including coronaviruses.</p><p>In this article, we summarize different classes of drugs with antiviral activity that have a repurposing potential (<xref rid="jcm-09-02441-t001" ref-type="table">Table 1</xref>). Some active ingredients or excipients described here have activity against other types of viruses, thus suggesting potential broad-spectrum applications. Clearly, none of the therapies reported in the present article are suggested for clinical use outside a clinical experimental setting.</p><p>In our analysis, seven main categories of drugs contained in topical ophthalmic preparations were considered for their widespread use among patients (excipients, antiseptics, artificial tears, anti-glaucoma medications, antibiotics/antifungals, antiallergic eye drops, and anti-inflammatory ophthalmic preparations).</p></sec><sec id="sec3-jcm-09-02441"><title>3. Literature Review</title><p>A review of the literature for original articles published up to 23 May 2020 was conducted, utilizing Pubmed, Web of Science, Embase, Google Scholar, and Scopus Databases, using the terms &#x0201c;antiviral&#x0201d; and each of the following words relating to a number of topical ophthalmic medications (Bolean operator &#x02018;AND&#x02019;): &#x0201c;artificial tear&#x0201d;, &#x0201c;antiseptic&#x0201d;, &#x0201c;antibiotic&#x0201d;, &#x0201c;anti-glaucoma&#x0201d;, &#x0201c;antiallergic&#x0201d;, &#x0201c;anti-inflammatory&#x0201d;, &#x0201c;preservatives&#x0201d;, &#x0201d;buffering agents&#x0201d;, &#x0201c;excipients&#x0201d;, and &#x0201c;antimicrobials&#x0201d;, without any limitation. In addition, manual screening was performed on the reference list of recovered studies for any additional research.</p><p>Four independent investigators (P.E.N., L.M., P.G., M.B.) carried out the research. The duplicates have been removed. All titles and abstracts of all citations were analyzed individually. Full texts of the articles deemed potentially eligible were obtained and assessed individually for eligibility.</p><p>From 2138 articles retrieved using these searches, we selected 94 papers for our review. In particular, studies that did not focus on the antiviral effect of substances commonly contained in topical ophthalmic preparations for different purposes and documents without new insights into a repurposing potential were excluded.</p></sec><sec id="sec4-jcm-09-02441"><title>4. Preservatives and Buffering Agents (Excipients)</title><p>A level of antimicrobial activity is provided by most eye drops and ophthalmic ointments through the use of preservatives, e.g., in association with artificial tears, anti-glaucoma medications, miotics, anti-inflammatories (nonsteroidal anti-inflammatory drugs, anti-allergics, corticosteroids), or antimicrobial formations (antibacterials, antifungals, antivirals). These chemical additives permit a reduction of ocular infections due to contaminated bottles and a prolonged efficacy of active ingredients or other excipients (i.e., maintaining their functionality and decreasing their biodegradation). For these purposes, oxidants (which deactivate the intracellular enzymes of the microbes and/or alter their nucleic acids, as well as other proteins and lipid components), detergents or surfactants (which non-specifically damage cell membranes), metabolic inhibitors, and chelating agents are commonly used in eye drops [<xref rid="B10-jcm-09-02441" ref-type="bibr">10</xref>].</p><p>The most widely used preservatives in the market are benzalkonium chloride (BAK; a detergent frequently used in concentration varying from 0.015% to 0.05%), sodium perborate (an oxidative agent that acts by forming hydrogen peroxide), chlorobutanol (detergent), methyl paraben (chelating agent), and stabilized thimerosal (organomercurial). In addition, although disodium-ethylene diamine tetra-acetate (EDTA) and phosphate-buffered saline are not considered as preservatives, they are often included in the formulations of the eye drops as buffering agents [<xref rid="B10-jcm-09-02441" ref-type="bibr">10</xref>].</p><p>Although an antiviral effect is theoretically possible with all the aforementioned preservatives, those that have so far proven a potential efficacy are as follows: sodium perborate (and related hydrogen peroxide), stabilized oxychloro complex (Purite, an oxidative agent), citric acid (chelating agent/buffering agent), sodium bicarbonate (buffering agent), and boric acid (buffering agent) [<xref rid="B11-jcm-09-02441" ref-type="bibr">11</xref>,<xref rid="B12-jcm-09-02441" ref-type="bibr">12</xref>,<xref rid="B13-jcm-09-02441" ref-type="bibr">13</xref>,<xref rid="B14-jcm-09-02441" ref-type="bibr">14</xref>].</p><p>Counterintuitively, incongruous data concern quaternary ammonium salt derivates (e.g., BAK) [<xref rid="B13-jcm-09-02441" ref-type="bibr">13</xref>,<xref rid="B15-jcm-09-02441" ref-type="bibr">15</xref>,<xref rid="B16-jcm-09-02441" ref-type="bibr">16</xref>,<xref rid="B17-jcm-09-02441" ref-type="bibr">17</xref>,<xref rid="B18-jcm-09-02441" ref-type="bibr">18</xref>,<xref rid="B19-jcm-09-02441" ref-type="bibr">19</xref>]. In fact, although the latter are generally considered to have virucidal activity against all lipid enveloped viruses [<xref rid="B13-jcm-09-02441" ref-type="bibr">13</xref>], some authors claim their inefficiency against SARS-CoV-2 [<xref rid="B15-jcm-09-02441" ref-type="bibr">15</xref>,<xref rid="B17-jcm-09-02441" ref-type="bibr">17</xref>,<xref rid="B19-jcm-09-02441" ref-type="bibr">19</xref>]. In this sense, a question that remains unanswered is as to whether intact RNA alone is an infectious agent, in particular after the COVID-19 virus has lost its envelope due to surfactant-mediated destruction (similar to non-enveloped viruses) [<xref rid="B15-jcm-09-02441" ref-type="bibr">15</xref>,<xref rid="B17-jcm-09-02441" ref-type="bibr">17</xref>]. Moreover, BAK is a preservative surfactant widely used in eye-drop formulations, but it has many issues regarding its capacity to alter the corneal epithelium, thus potentially increasing permeability of compounds (as active ingredients) and/or infectious agents through this anatomical barrier [<xref rid="B11-jcm-09-02441" ref-type="bibr">11</xref>].</p><p>On the other hand, thimerosal has been removed from most of the eye drops for its toxic effects on ocular surface epithelia [<xref rid="B10-jcm-09-02441" ref-type="bibr">10</xref>].</p></sec><sec id="sec5-jcm-09-02441"><title>5. Antiseptic-Disinfectant Agents</title><p>Disinfectants represent chemical agents mainly used to inactivate or destroy microorganisms on inert surfaces. On the contrary, antiseptics destroy microorganisms on living tissue. Given the lack of specific antiviral treatments for COVID-19, a deeper knowledge of the potential efficacy of available antiseptic disinfectants on viruses is very desirable. Clearly, the time of exposure, the concentration, and the formulation of chemicals are all factors influencing the antiviral action of each agent.</p><p>In general, several antiseptic disinfectants are currently recommended to prevent environmental transmission of the COVID-19 virus. Nevertheless, enveloped viruses, such as SARS-CoV-2, are not easily inactivated by different antiseptic disinfectants, such as quaternary ammoniums compounds, hexamidine, phenolic compounds, or chlorhexidine [<xref rid="B17-jcm-09-02441" ref-type="bibr">17</xref>].</p><p>With regards to the formulations available for ophthalmological use, the most common and potentially interesting are those based on povidone iodine and sodium hypochlorite. Of note, some authors demonstrated that, in suspension tests and for contact times of 5 min, povidone iodine (&#x0003e;0.75% free iodine) can inactivate SARS-CoV-2 infectivity in ~4 log<sub>10</sub> or more [changes in viral load can be reported as a logarithmic change (in powers of 10) in copies of a specific virus in a defined space], as recommended by the European Standard [<xref rid="B19-jcm-09-02441" ref-type="bibr">19</xref>,<xref rid="B20-jcm-09-02441" ref-type="bibr">20</xref>,<xref rid="B21-jcm-09-02441" ref-type="bibr">21</xref>]. Additionally, sodium hypochlorite (at least 0.21%) has shown efficacy against mouse hepatitis virus (a species of coronavirus) and, consequently, should also be able to inactivate SARS-CoV-2 [<xref rid="B19-jcm-09-02441" ref-type="bibr">19</xref>].</p><p>The other disinfectants include peroxides and peracids, which promote the production of free radicals that oxidize essential nucleic acids, lipids, and proteins that lead to virucidal activity (e.g., 0.5% hydrogen peroxide with an exposure time of 1 min) [<xref rid="B19-jcm-09-02441" ref-type="bibr">19</xref>,<xref rid="B20-jcm-09-02441" ref-type="bibr">20</xref>,<xref rid="B21-jcm-09-02441" ref-type="bibr">21</xref>,<xref rid="B22-jcm-09-02441" ref-type="bibr">22</xref>].</p></sec><sec id="sec6-jcm-09-02441"><title>6. Artificial Tears</title><p>Considering that the prevalence of dry eye disease ranges from 5 to 50% in the general population, it is presumable that this category of eye drops is among the most used by patients. It is interesting to note that a number of substances contained in these formulations (excluding preservatives and buffering agents) are endowed of antiviral action. In particular, we would like to recall the following substances: high molecular weight hyaluronic acid, trehalose, carbopol, and lactoferrin, as well as chamomile oils or extracts of <italic>Echinacea purpurea</italic>, <italic>Rubus fruticosus</italic> (blackberry), <italic>Aloe vera</italic> (i.e., its exudates of aloe emodin), <italic>Ginkgo biloba</italic>, <italic>Centella asiatica</italic>, and <italic>Foeniculum vulgare</italic> (Fennel) [<xref rid="B23-jcm-09-02441" ref-type="bibr">23</xref>,<xref rid="B24-jcm-09-02441" ref-type="bibr">24</xref>,<xref rid="B25-jcm-09-02441" ref-type="bibr">25</xref>,<xref rid="B26-jcm-09-02441" ref-type="bibr">26</xref>,<xref rid="B27-jcm-09-02441" ref-type="bibr">27</xref>,<xref rid="B28-jcm-09-02441" ref-type="bibr">28</xref>,<xref rid="B29-jcm-09-02441" ref-type="bibr">29</xref>,<xref rid="B30-jcm-09-02441" ref-type="bibr">30</xref>,<xref rid="B31-jcm-09-02441" ref-type="bibr">31</xref>,<xref rid="B32-jcm-09-02441" ref-type="bibr">32</xref>,<xref rid="B33-jcm-09-02441" ref-type="bibr">33</xref>,<xref rid="B34-jcm-09-02441" ref-type="bibr">34</xref>,<xref rid="B35-jcm-09-02441" ref-type="bibr">35</xref>,<xref rid="B36-jcm-09-02441" ref-type="bibr">36</xref>,<xref rid="B37-jcm-09-02441" ref-type="bibr">37</xref>,<xref rid="B38-jcm-09-02441" ref-type="bibr">38</xref>,<xref rid="B39-jcm-09-02441" ref-type="bibr">39</xref>].</p><p>Other ingredients presumed to have mild virucidal action are glycerol, l-carnitine, and ozonated oils (O3-Oil) [<xref rid="B40-jcm-09-02441" ref-type="bibr">40</xref>,<xref rid="B41-jcm-09-02441" ref-type="bibr">41</xref>,<xref rid="B42-jcm-09-02441" ref-type="bibr">42</xref>,<xref rid="B43-jcm-09-02441" ref-type="bibr">43</xref>,<xref rid="B44-jcm-09-02441" ref-type="bibr">44</xref>].</p><p>Curiously, excipients commonly classified as antioxidants, i.e., acetylcysteine, vitamin A, vitamin C (ascorbate), have been shown a variable grade of antiviral action [<xref rid="B41-jcm-09-02441" ref-type="bibr">41</xref>,<xref rid="B45-jcm-09-02441" ref-type="bibr">45</xref>,<xref rid="B46-jcm-09-02441" ref-type="bibr">46</xref>,<xref rid="B47-jcm-09-02441" ref-type="bibr">47</xref>,<xref rid="B48-jcm-09-02441" ref-type="bibr">48</xref>]. Of note, vitamin D has been shown to improve innate or therapeutic antiviral response to various viruses [<xref rid="B49-jcm-09-02441" ref-type="bibr">49</xref>,<xref rid="B50-jcm-09-02441" ref-type="bibr">50</xref>].</p><p>Overall, artificial tears have been shown to possess several mechanisms of antiviral action against a wide range of DNA or RNA viruses [<xref rid="B23-jcm-09-02441" ref-type="bibr">23</xref>,<xref rid="B24-jcm-09-02441" ref-type="bibr">24</xref>,<xref rid="B25-jcm-09-02441" ref-type="bibr">25</xref>,<xref rid="B26-jcm-09-02441" ref-type="bibr">26</xref>,<xref rid="B27-jcm-09-02441" ref-type="bibr">27</xref>,<xref rid="B28-jcm-09-02441" ref-type="bibr">28</xref>,<xref rid="B29-jcm-09-02441" ref-type="bibr">29</xref>,<xref rid="B30-jcm-09-02441" ref-type="bibr">30</xref>,<xref rid="B31-jcm-09-02441" ref-type="bibr">31</xref>,<xref rid="B32-jcm-09-02441" ref-type="bibr">32</xref>,<xref rid="B33-jcm-09-02441" ref-type="bibr">33</xref>,<xref rid="B34-jcm-09-02441" ref-type="bibr">34</xref>,<xref rid="B35-jcm-09-02441" ref-type="bibr">35</xref>,<xref rid="B36-jcm-09-02441" ref-type="bibr">36</xref>,<xref rid="B37-jcm-09-02441" ref-type="bibr">37</xref>,<xref rid="B38-jcm-09-02441" ref-type="bibr">38</xref>,<xref rid="B39-jcm-09-02441" ref-type="bibr">39</xref>,<xref rid="B40-jcm-09-02441" ref-type="bibr">40</xref>,<xref rid="B41-jcm-09-02441" ref-type="bibr">41</xref>,<xref rid="B42-jcm-09-02441" ref-type="bibr">42</xref>,<xref rid="B43-jcm-09-02441" ref-type="bibr">43</xref>,<xref rid="B44-jcm-09-02441" ref-type="bibr">44</xref>,<xref rid="B45-jcm-09-02441" ref-type="bibr">45</xref>,<xref rid="B46-jcm-09-02441" ref-type="bibr">46</xref>,<xref rid="B47-jcm-09-02441" ref-type="bibr">47</xref>,<xref rid="B48-jcm-09-02441" ref-type="bibr">48</xref>,<xref rid="B49-jcm-09-02441" ref-type="bibr">49</xref>,<xref rid="B50-jcm-09-02441" ref-type="bibr">50</xref>]. Interestingly, some polymer constituents (e.g., high molecular weight hyaluronic acid) and natural extracts (e.g., <italic>Ginkgo biloba</italic>) have even shown that they can inhibit some viruses belonging to the Coronaviridae family (e.g., porcine parvovirus). In addition, some electrolytes contained in artificial tears with the function of maintaining the ocular surface homeostasis can also have an antiviral effect. For example, zinc (0.25%), which is used as an excipient or in astringent eye drops, has shown that it can inhibit SARS-CoV-2 polymerase activity, blocking viral replication [<xref rid="B51-jcm-09-02441" ref-type="bibr">51</xref>].</p><p>Considering the large market of this category of eye drops, in particular those based on hyaluronic acid, it is possible to presume that their use may play an important role in protecting the ocular surface from viral infections in a variable number of patients.</p><p>On the other hand, topical application of chloroquine may also have a repurposing potential. Chloroquine is an anti-malarial drug with immunomodulatory functions that has demonstrated an antiviral effect through the inhibition of the pH linked steps of viral replication of various viruses (e.g., retroviruses, flaviviruses, and coronaviruses), including SARS-CoV-2. In eye drops, chloroquine has been recently used at a concentration of 0.03% in patients with dry eye [<xref rid="B52-jcm-09-02441" ref-type="bibr">52</xref>].</p></sec><sec id="sec7-jcm-09-02441"><title>7. Anti-Glaucoma Eye Drops</title><p>Glaucoma is the leading cause of global irreversible blindness. Present estimates of global glaucoma prevalence are not up-to-date and focus mainly on European ancestry populations. The global prevalence of glaucoma for the population aged 40&#x02013;80 years is 3.54% and rises progressively by age.</p><p>Some drugs used for glaucoma have been shown to affect the clinical course of viral infections. For example, latanoprost has been associated with herpes virus keratitis, potentially increasing the severity and recurrence of the disease [<xref rid="B53-jcm-09-02441" ref-type="bibr">53</xref>,<xref rid="B54-jcm-09-02441" ref-type="bibr">54</xref>]. Similar behavior has been observed with tafluprost, bimatoprost, and travoprost [<xref rid="B55-jcm-09-02441" ref-type="bibr">55</xref>,<xref rid="B56-jcm-09-02441" ref-type="bibr">56</xref>,<xref rid="B57-jcm-09-02441" ref-type="bibr">57</xref>].</p><p>Conversely, timolol maleate acts as an antiviral agent and it is used in the treatment of viral infections, such as herpes simplex infections [<xref rid="B58-jcm-09-02441" ref-type="bibr">58</xref>].</p><p>Of interest, dorzolamide showed antiviral action against oseltamivir-resistant influenza by an in silico screening, specifically targeting mutant viral neuraminidase [<xref rid="B59-jcm-09-02441" ref-type="bibr">59</xref>]. Brinzolamide also showed to be a moderate inhibitor of viral growth of the H3N2 virus and H1N1 influenza viruses and a weak inhibitor of avian H5N2 and H7N1 influenza viruses [<xref rid="B60-jcm-09-02441" ref-type="bibr">60</xref>].</p><p>Overall, glaucoma drugs may have a synergistic action against viral infections, both for the active ingredients and excipients, but careful monitoring should be suggested for patients treated with prostaglandin analogues.</p></sec><sec id="sec8-jcm-09-02441"><title>8. Antibiotics and Other Antimicrobials</title><p>An antibiotic is a type of antimicrobial agent used to fight and prevent bacterial infections. They can kill and/or inhibit the growth of bacteria. A limited number of antibiotics also have antiviral activity, since viruses do not have cell walls that can be attacked by antibiotics (but a protective protein coat) and cannot reproduce on their own, as bacteria do, having to colonize healthy cells and reprogram them to create new viruses.</p><p>Categories of antibiotics with antiviral potential include macrolides (e.g., azithromycin, which demonstrated activity against SARS-CoV-2), tetracyclines (tetracycline, doxycycline, minocycline, which have been proposed in the treatment of COVID-19), fluoroquinolones (e.g., ciprofloxacin, levofloxacin, ofloxacin, which have shown efficacy against polyomavirus BK and influenza virus), aminoglycosides (e.g., on Japanese encephalitis and influenza A virus infection), chloramphenicol (e.g., on human Herpesviridae family), Colistin (polymyxin E, for example on mycobacteriophage D29 infection),and fusidic acid (e.g., on human immunodeficiency virus and John Cunningham virus infection) [<xref rid="B61-jcm-09-02441" ref-type="bibr">61</xref>,<xref rid="B62-jcm-09-02441" ref-type="bibr">62</xref>,<xref rid="B63-jcm-09-02441" ref-type="bibr">63</xref>,<xref rid="B64-jcm-09-02441" ref-type="bibr">64</xref>,<xref rid="B65-jcm-09-02441" ref-type="bibr">65</xref>,<xref rid="B66-jcm-09-02441" ref-type="bibr">66</xref>,<xref rid="B67-jcm-09-02441" ref-type="bibr">67</xref>,<xref rid="B68-jcm-09-02441" ref-type="bibr">68</xref>,<xref rid="B69-jcm-09-02441" ref-type="bibr">69</xref>,<xref rid="B70-jcm-09-02441" ref-type="bibr">70</xref>].</p><p>Even some antifungals (which are rarely used in ophthalmology) can have a virucidal effect (e.g., amphotericin B, itraconazole, posaconazole) [<xref rid="B71-jcm-09-02441" ref-type="bibr">71</xref>,<xref rid="B72-jcm-09-02441" ref-type="bibr">72</xref>,<xref rid="B73-jcm-09-02441" ref-type="bibr">73</xref>].</p></sec><sec id="sec9-jcm-09-02441"><title>9. Antiallergic Eye Drops</title><p>Allergic eye diseases are another group of pathologies that are very frequent in the general population [<xref rid="B74-jcm-09-02441" ref-type="bibr">74</xref>]. It is estimated that around 20% of the world&#x02019;s population has an allergic disease, of which up to 60% has ocular involvement [<xref rid="B75-jcm-09-02441" ref-type="bibr">75</xref>]. For these reasons, antiallergic eye drops represent a large percentage of all eye drops used by patients. The most severe chronic forms, e.g., atopic keratoconjunctivitis, can be debilitating, particularly when associated with a significant tear film dysfunction [<xref rid="B76-jcm-09-02441" ref-type="bibr">76</xref>]. Complex responses of the immune system are implicated in the activation and maintenance of these chronic or recurrent inflammatory diseases [<xref rid="B77-jcm-09-02441" ref-type="bibr">77</xref>]. Consequently, they may require prolonged treatments with anti-inflammatory agents in the most severe cases.</p><p>Surprisingly, several antihistamines, such as chlorcyclizine, chlorpheniramine, and diphenhydramine, have demonstrated antiviral action against hepatitis C virus (HCV), filoviruses (consisting of Ebola virus, Marburg virus, and Cuevavirus), and Influenza A virus infection [<xref rid="B78-jcm-09-02441" ref-type="bibr">78</xref>,<xref rid="B79-jcm-09-02441" ref-type="bibr">79</xref>,<xref rid="B80-jcm-09-02441" ref-type="bibr">80</xref>]. Of note, ketotifen fumarate has proven to attenuate dengue virus infection [<xref rid="B81-jcm-09-02441" ref-type="bibr">81</xref>]. Controversial results of antihistamines in antiviral effects appear to be associated with herpes simplex virus (HSV) infection [<xref rid="B82-jcm-09-02441" ref-type="bibr">82</xref>].</p><p>A group of Flavonoids, plant polyphenols that give flavor and color to vegetables and fruits, has recently gained importance in the pharmaceutical field through its beneficial effects in the prevention or treatment of different ocular diseases, including allergic eye disorders, dry eye disease, diabetic retinopathy, macular degeneration, and cataracts [<xref rid="B83-jcm-09-02441" ref-type="bibr">83</xref>,<xref rid="B84-jcm-09-02441" ref-type="bibr">84</xref>]. In particular, antiviral effects have been observed against HSV-1, polio-virus type 1, and respiratory syncytial virus (RSV).</p><p>Some topical immunomodulators, such as cyclosporine (also used in dry eye therapy), have also shown antiviral action against HCV, Flavivirus and influenza virus [<xref rid="B85-jcm-09-02441" ref-type="bibr">85</xref>,<xref rid="B86-jcm-09-02441" ref-type="bibr">86</xref>,<xref rid="B87-jcm-09-02441" ref-type="bibr">87</xref>].</p></sec><sec id="sec10-jcm-09-02441"><title>10. Anti-Inflammatory Ophthalmic Preparations</title><p>Another interesting category of drugs contained in ophthalmic preparation is that of active substances in reducing inflammation with a broad spectrum of other effects. These drugs are commonly subdivided in two categories: non-steroidal anti-inflammatory drugs (NSAIDs) and steroids. Generally, these eye drops, or ophthalmic ointments, are used to depress or prevent various types of eye inflammations (e.g., during peri-surgical period or for uveitis) or to control ocular pain (e.g., discomfort symptoms after cataract surgery).</p><p>Interestingly, some NSAIDs have shown antiviral action. However, a short premise is necessary to understand their function. With regards to the control of recurrences of HSV, latent HSV activation is generally associated with an increase in prostaglandins (PG), which presumably suppress the inhibitory effect of interferon (IFN) on replication HSV. In this sense, indometacin and bromfenac has proven to inhibit HSV-1 replication as they depress PG levels without altering IFN levels [<xref rid="B88-jcm-09-02441" ref-type="bibr">88</xref>,<xref rid="B89-jcm-09-02441" ref-type="bibr">89</xref>]. On the contrary, steroids may adversely influence, by suppressing the overall inflammatory response, the processes acting to inhibit herpetic viruses. Nevertheless, a short course of topical steroids (e.g., dexamethasone) may be useful for patients with acute, presumed, and aspecific viral conjunctivitis [<xref rid="B90-jcm-09-02441" ref-type="bibr">90</xref>,<xref rid="B91-jcm-09-02441" ref-type="bibr">91</xref>,<xref rid="B92-jcm-09-02441" ref-type="bibr">92</xref>].</p></sec><sec sec-type="discussion" id="sec11-jcm-09-02441"><title>11. Discussion and Conclusions</title><p>Although systemic and topical (eye drops/ophthalmic ointments) antiviral medications have been utilized in a small number of cases by different authors, no specific antivirals are currently available for SARS-CoV-2 associated conjunctivitis. Overall, this pathology of the ocular surface still leaves many questions unanswered [<xref rid="B3-jcm-09-02441" ref-type="bibr">3</xref>], being associated with some controversial and unclear data.</p><p>First, a patient with this conjunctivitis as an earlier symptom may have a negative conjunctival sac SARS-CoV-2 test, but also the opposite may be observed. According to a recent meta-analysis on 1167 patients, the overall rate of conjunctivitis appears to be 1.1% (13/1149), of which 3% (6/195) and 0.7% (7/954) was found in severe and non-severe forms of COVID-19, respectively [<xref rid="B93-jcm-09-02441" ref-type="bibr">93</xref>]. Nevertheless, an increasing number of conjunctivitis case reports are continuously appearing in literature.</p><p>Second, SARS-CoV-2 conjunctivitis has been described as a mild follicular conjunctivitis otherwise indistinguishable from other viral causes [<xref rid="B94-jcm-09-02441" ref-type="bibr">94</xref>]. In addition, other features of ocular surface involvement include unilateral or bilateral bulbar conjunctiva hyperemia alone or in association with chemosis, follicular reaction of the palpebral conjunctiva, watery discharge, epiphora, and mild eyelid edema.</p><p>Another unresolved question is whether conjunctivitis is directly related to virus infection or represents an allergic immune response to the virus [<xref rid="B95-jcm-09-02441" ref-type="bibr">95</xref>].</p><p>Generally, viral conjunctivitis (of unknown origin) does not require treatment, although antibiotics, steroids, and artificial tear drops are often prescribed to relieve inflammation signs and symptoms. Most medicines currently available for the treatment of viral conjunctivitis are directed against herpes and adenovirus infections, and infectious diseases of the eye caused by RNA viruses (such as influenza, RSV, or coronavirus) lack targeted antiviral medications. Skevaki et al. recommend the use of oseltamivir, ganciclovir, and other drugs for treatment and prevention during the onset of conjunctivitis symptoms or a history of eye contact [<xref rid="B96-jcm-09-02441" ref-type="bibr">96</xref>].</p><p>According to Zhou [<xref rid="B97-jcm-09-02441" ref-type="bibr">97</xref>], the rarity of viral conjunctivitis in SARS-CoV-2 infection may exist in three interpretations. Firstly, the expression of the ACE2 protein on conjunctival epithelial cell membranes is much less than that in human lung and kidney tissues [<xref rid="B8-jcm-09-02441" ref-type="bibr">8</xref>,<xref rid="B9-jcm-09-02441" ref-type="bibr">9</xref>]. Secondly, the binding capability of the ACE2 protein on conjunctival epithelial cells to SARS-CoV spike protein is much lower than that in lung tissues [<xref rid="B98-jcm-09-02441" ref-type="bibr">98</xref>]. Thirdly, the protective effect of the antimicrobial agents in tears, including lactoferrin and secretory IgA, and constant tear rinsing on the ocular surface, which could eliminate the viruses, dropped onto the ocular surface and into the nasal cavity through the nasolacrimal duct [<xref rid="B3-jcm-09-02441" ref-type="bibr">3</xref>].</p><p>However, the present study shows that a large proportion of ophthalmic preparations, utilized for different ocular diseases, contain substances with an intrinsic, broad spectrum, antiviral activity, which has already been used clinically in the past for other (non-COVID-19) viral infections. In particular, here we want to emphasize the potential usefulness of artificial tears and iodine/sodium hypochlorite eye drops to promote the reduction of viral load on the ocular surface by removing the virus or by means of a direct virucidal action.</p><p>A very interesting aspect to note is that a large portion of these eye drops, or ophthalmic ointments are registered as over-the-counter (OTC). As such, they can be easily and widely purchased by patients without the need for a prescription or an ophthalmological consultation. For example, artificial tears are not only sold in pharmacies, but they are often found in supermarkets or optical stores.</p><p>Clearly, the use of any eye drops (e.g., saline solution) may also facilitate the reduction of viral load through the washing of infectious agents [<xref rid="B99-jcm-09-02441" ref-type="bibr">99</xref>]. Accordingly, the excretion of elements present in human tears towards the lid skin occurs not only in overflow conditions due to a large volume, but also because of a mechanism related to the characteristics of high fluid dynamics (turbulence of the meniscus) [<xref rid="B100-jcm-09-02441" ref-type="bibr">100</xref>,<xref rid="B101-jcm-09-02441" ref-type="bibr">101</xref>]. Of note, the volume of a drop obtained from a bottle of ophthalmic solution generally ranges from 25 to 70 &#x000b5;L, while the ocular surface may contain much less liquid [<xref rid="B102-jcm-09-02441" ref-type="bibr">102</xref>]. For all these reasons, each administration of eye drops implies a wash-out of any substances above the epithelia of the ocular surface.</p><p>As a comparison, a different concept is that concerning ophthalmic ointments. In fact, the latter do not favor the washing of infectious agents but can release drugs for a long time. This aspect can be advantageous if the substance has an antiviral effect (a presumably common situation), while in the case of steroid ointments, for example, it could be very disadvantageous with detrimental effects on the ocular surface epithelia (e.g., following herpes virus infection).</p><p>It is possible that a fraction of patients affected by COVID-19 regularly use any type of these topical medications, suggesting an alternative explanation for the limited detection of viruses in tears and on the ocular surface observed in some series of COVID-19 patients. Specific studies might enlighten on this hypothesis.</p><p>At present, the drug repurposing approach is widely used to identify potential therapies for different diseases. In recent years, it has gained a lot of popularity in the scientific community for the ability to reuse drugs already available for various diseases beyond their original indication. This approach is based on the principle that different diseases share overlapping molecular pathways and various drugs have multiple protein targets [<xref rid="B103-jcm-09-02441" ref-type="bibr">103</xref>]. The advantages of reusing approved drugs in this way include reducing costs, time, and risks associated with the experimental phases of <italic>de novo</italic> drugs [<xref rid="B104-jcm-09-02441" ref-type="bibr">104</xref>]. Clearly, the drug development approach (e.g., regarding virus-specific vaccines or small molecules) is inadequate to immediately address the problems associated with a pandemic such as COVID-19. The concept of redefining the potentiality of existing drugs is one that most quickly meets the needs of a population under a health emergency.</p><p>It should be noted that, if the use of such drugs re-proposed individually may be clinically ineffective, their carefully evaluated combinations could benefit patients, which happened with human immunodeficiency virus (HIV) during the 1990s [<xref rid="B105-jcm-09-02441" ref-type="bibr">105</xref>]. In this sense, various eye drops simultaneously contain several substances with antiviral action, e.g., active ingredients, buffering agents, preservatives, or other excipients. In the future, one aspect that will determine the effectiveness of this drug repurposing strategy will be the comparison, positive or negative, with the treatments developed specifically for COVID-19 (in particular, vaccines or drugs). In fact, a feature of these repurposed drugs is their non-specificity for an infectious agent (e.g., SARS-CoV-2), which can become a significant problem in the case of sudden drug resistance or more virulent strains. However, the discovery of vaccines and antibodies generally takes up to a decade and may be slowed by the potential for attenuated antigenicity of epitopes due to the genetic drift of the virus.</p><p>Overall, the results of this work strongly suggest that ophthalmic preparations represent a vast reservoir of potential candidates for drug repurposing for use as antiviral therapeutics. Here, we have analyzed only the main categories of substances contained in ophthalmic preparations with re-profiling potential. However, there are also other groups of drugs, such as antihypertensives and anticoagulants, which might unexpectedly give interesting results by topical application (e.g., ACE inhibitors, or heparin sodium) [<xref rid="B106-jcm-09-02441" ref-type="bibr">106</xref>,<xref rid="B107-jcm-09-02441" ref-type="bibr">107</xref>,<xref rid="B108-jcm-09-02441" ref-type="bibr">108</xref>]. In this sense, tea tree oil (TTO) is another therapeutic option for viral infections, which is widely used in gel formulations to be applied on the eyelid skin (not inside the eye). In several studies, TTO has demonstrated anti-viral action against HSV, Influenza virus A/PR/8, and Tobacco Mosaic virus (a Tobamovirus that infects a wide range of plants) [<xref rid="B109-jcm-09-02441" ref-type="bibr">109</xref>,<xref rid="B110-jcm-09-02441" ref-type="bibr">110</xref>,<xref rid="B111-jcm-09-02441" ref-type="bibr">111</xref>].</p><p>In addition, particular attention is recommended in the follow-up of glaucomatous patients treated with prostaglandin analogues or uveitic patients under steroids, for which the use of lubricants is particularly indicated for different reasons, e.g., limiting in situ virus replication and epithelial damage.</p><p>Clearly, all information reported in this article is not intended to guide clinical decisions, and any potential therapy reported here should only be considered as a proposal to be evaluated in the context of clinical trials.</p></sec></body><back><notes><title>Author Contributions</title><p>Conceived and designed the manuscript: P.E.N. 70%, M.F. 30%.Wrote the manuscript: P.E.N. 55%, L.M. 10%, P.G. 10%, M.B. 10%, M.F. 15%. Revised the paper: P.E.N. 60%, L.M. 5%, P.G. 5%, M.B. 5%, M.F. 25%. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research received no external funding.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>Pietro Emanuele Napoli, Lorenzo Mangoni, Pietro Gentile, Mirco Braghiroli, Maurizio Fossarello-none to declare. No conflicting relationship exists for any author.</p></notes><ref-list><title>References</title><ref id="B1-jcm-09-02441"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Napoli</surname><given-names>P.E.</given-names></name><name><surname>Nioi</surname><given-names>M.</given-names></name></person-group><article-title>Global Spread of Coronavirus Disease 2019 and Malaria: An Epidemiological Paradox in the Early Stage of a Pandemic</article-title><source>J. Clin. Med.</source><year>2020</year><volume>9</volume><elocation-id>1138</elocation-id><pub-id pub-id-type="doi">10.3390/jcm9041138</pub-id><?supplied-pmid 32316118?><pub-id pub-id-type="pmid">32316118</pub-id></element-citation></ref><ref id="B2-jcm-09-02441"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Napoli</surname><given-names>P.E.</given-names></name><name><surname>Nioi</surname><given-names>M.</given-names></name><name><surname>D&#x02019;Aloja</surname><given-names>E.</given-names></name><name><surname>Fossarello</surname><given-names>M.</given-names></name></person-group><article-title>Safety Recommendations and Medical Liability in Ocular Surgery during the COVID-19 Pandemic: An Unsolved Dilemma</article-title><source>J. Clin. Med.</source><year>2020</year><volume>9</volume><elocation-id>1403</elocation-id><pub-id pub-id-type="doi">10.3390/jcm9051403</pub-id><?supplied-pmid 32397530?><pub-id pub-id-type="pmid">32397530</pub-id></element-citation></ref><ref id="B3-jcm-09-02441"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Napoli</surname><given-names>P.E.</given-names></name><name><surname>Nioi</surname><given-names>M.</given-names></name><name><surname>D&#x02019;Aloja</surname><given-names>E.</given-names></name><name><surname>Fossarello</surname><given-names>M.</given-names></name></person-group><article-title>The Ocular Surface and the Coronavirus Disease 2019: Does a Dual &#x02018;Ocular Route&#x02019; Exist?</article-title><source>J. Clin. Med.</source><year>2020</year><volume>9</volume><elocation-id>1269</elocation-id><pub-id pub-id-type="doi">10.3390/jcm9051269</pub-id><?supplied-pmid 32353982?><pub-id pub-id-type="pmid">32353982</pub-id></element-citation></ref><ref id="B4-jcm-09-02441"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>J.</given-names></name><name><surname>Tong</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>D.</given-names></name></person-group><article-title>Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection</article-title><source>J. Med. Virol.</source><year>2020</year><volume>92</volume><fpage>589</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1002/jmv.25725</pub-id><?supplied-pmid 32100876?><pub-id pub-id-type="pmid">32100876</pub-id></element-citation></ref><ref id="B5-jcm-09-02441"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>C.-W.</given-names></name><name><surname>Liu</surname><given-names>X.-F.</given-names></name><name><surname>Jia</surname><given-names>Z.-F.</given-names></name></person-group><article-title>2019-nCoV transmission through the ocular surface must not be ignored</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>e39</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30313-5</pub-id><pub-id pub-id-type="pmid">32035510</pub-id></element-citation></ref><ref id="B6-jcm-09-02441"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X.J.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Dai</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Jin</surname><given-names>W.</given-names></name></person-group><article-title>Novel coronavirus disease with conjunctivitis and conjunctivitis as first symptom: Two cases report</article-title><source>Chin. J. Exp. Ophthalmol.</source><year>2020</year><volume>38</volume><pub-id pub-id-type="doi">10.0376/cma.j.cn.115989-20200303-00133</pub-id></element-citation></ref><ref id="B7-jcm-09-02441"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X.J.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>C.Z.</given-names></name><name><surname>Yang</surname><given-names>A.</given-names></name><name><surname>Jin</surname><given-names>W.</given-names></name></person-group><article-title>Ophthalmologists&#x02019; strategy for the prevention and control of coronavirus pneumonia with conjunctivitis or with conjunctivitis as the first symptom</article-title><source>Chin. J. Exp. Ophthalmol.</source><year>2020</year><volume>38</volume><fpage>276</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.3760/cma.j.issn.2095-0160.2020.0002</pub-id></element-citation></ref><ref id="B8-jcm-09-02441"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>W.-J.</given-names></name><name><surname>Ni</surname><given-names>Z.-Y.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>W.-H.</given-names></name><name><surname>Ou</surname><given-names>C.-Q.</given-names></name><name><surname>He</surname><given-names>J.-X.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Shan</surname><given-names>H.</given-names></name><name><surname>Lei</surname><given-names>C.-L.</given-names></name><name><surname>Hui</surname><given-names>D.S.</given-names></name><etal/></person-group><article-title>Clinical Characteristics of Coronavirus Disease 2019 in China</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>382</volume><fpage>1708</fpage><lpage>1720</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id><pub-id pub-id-type="pmid">32109013</pub-id></element-citation></ref><ref id="B9-jcm-09-02441"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>P.</given-names></name><name><surname>Duan</surname><given-names>F.</given-names></name><name><surname>Luo</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Qu</surname><given-names>X.</given-names></name><name><surname>Liang</surname><given-names>L.</given-names></name><name><surname>Wu</surname><given-names>K.</given-names></name></person-group><article-title>Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China</article-title><source>JAMA Ophthalmol.</source><year>2020</year><volume>138</volume><fpage>575</fpage><pub-id pub-id-type="doi">10.1001/jamaophthalmol.2020.1291</pub-id></element-citation></ref><ref id="B10-jcm-09-02441"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Epstein</surname><given-names>S.P.</given-names></name><name><surname>Ahdoot</surname><given-names>M.</given-names></name><name><surname>Marcus</surname><given-names>E.</given-names></name><name><surname>Asbell</surname><given-names>P.A.</given-names></name></person-group><article-title>Comparative Toxicity of Preservatives on Immortalized Corneal and Conjunctival Epithelial Cells</article-title><source>J. Ocul. Pharmacol. Ther.</source><year>2009</year><volume>25</volume><fpage>113</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1089/jop.2008.0098</pub-id><pub-id pub-id-type="pmid">19284328</pub-id></element-citation></ref><ref id="B11-jcm-09-02441"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>E.Y.</given-names></name></person-group><article-title>Balancing antimicrobial efficacy and toxicity of currently available topical ophthalmic preservatives</article-title><source>Saudi J. Ophthalmol.</source><year>2014</year><volume>28</volume><fpage>182</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1016/j.sjopt.2014.06.006</pub-id><?supplied-pmid 25278794?><pub-id pub-id-type="pmid">25278794</pub-id></element-citation></ref><ref id="B12-jcm-09-02441"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malik</surname><given-names>Y.S.</given-names></name><name><surname>Goyal</surname><given-names>S.M.</given-names></name></person-group><article-title>Virucidal efficacy of sodium bicarbonate on a food contact surface against feline calicivirus, a norovirus surrogate</article-title><source>Int. J. Food Microbiol.</source><year>2006</year><volume>109</volume><fpage>160</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/j.ijfoodmicro.2005.08.033</pub-id><?supplied-pmid 16540196?><pub-id pub-id-type="pmid">16540196</pub-id></element-citation></ref><ref id="B13-jcm-09-02441"><label>13.</label><element-citation publication-type="book"><article-title>List N: Disinfectants for Use against SARS-CoV-2</article-title><publisher-name>United States Environmental Protection Agency</publisher-name><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2">https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-05-18">(accessed on 18 May 2020)</date-in-citation></element-citation></ref><ref id="B14-jcm-09-02441"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez-Patlan</surname><given-names>D.</given-names></name><name><surname>Solis-Cruz</surname><given-names>B.</given-names></name><name><surname>M&#x000e9;ndez-Albores</surname><given-names>A.</given-names></name><name><surname>Latorre</surname><given-names>J.D.</given-names></name><name><surname>Hernandez-Velasco</surname><given-names>X.</given-names></name><name><surname>Tellez-Isaias</surname><given-names>G.</given-names></name><name><surname>L&#x000f3;pez-Arellano</surname><given-names>R.</given-names></name></person-group><article-title>Comparison of PrestoBlue<sup>&#x000ae;</sup> and plating method to evaluate antimicrobial activity of ascorbic acid, boric acid and curcumin in an in vitro gastrointestinal model</article-title><source>J. Appl. Microbiol.</source><year>2018</year><volume>124</volume><fpage>423</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1111/jam.13659</pub-id><?supplied-pmid 29215799?><pub-id pub-id-type="pmid">29215799</pub-id></element-citation></ref><ref id="B15-jcm-09-02441"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrank</surname><given-names>C.L.</given-names></name><name><surname>Minbiole</surname><given-names>K.P.C.</given-names></name><name><surname>Wuest</surname><given-names>W.M.</given-names></name></person-group><article-title>Are Quaternary Ammonium Compounds, the Workhorse Disinfectants, Effective against Severe Acute Respiratory Syndrome-Coronavirus-2?</article-title><source>ACS Infect. Dis.</source><year>2020</year><pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00265</pub-id></element-citation></ref><ref id="B16-jcm-09-02441"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>A.</given-names></name><name><surname>Payne</surname><given-names>D.</given-names></name></person-group><article-title>The action of three antiseptics/disinfectants against enveloped and non-enveloped viruses</article-title><source>J. Hosp. Infect.</source><year>1998</year><volume>38</volume><fpage>283</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1016/S0195-6701(98)90077-9</pub-id><pub-id pub-id-type="pmid">9602977</pub-id></element-citation></ref><ref id="B17-jcm-09-02441"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sattar</surname><given-names>S.A.</given-names></name><name><surname>Springthorpe</surname><given-names>V.S.</given-names></name><name><surname>Karim</surname><given-names>Y.</given-names></name><name><surname>Loro</surname><given-names>P.</given-names></name></person-group><article-title>Chemical disinfection of non-porous inanimate surfaces experimentally contaminated with four human pathogenic viruses</article-title><source>Epidemiol. Infect.</source><year>1989</year><volume>102</volume><fpage>493</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1017/S0950268800030211</pub-id><pub-id pub-id-type="pmid">2737256</pub-id></element-citation></ref><ref id="B18-jcm-09-02441"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabenau</surname><given-names>H.</given-names></name><name><surname>Kampf</surname><given-names>G.</given-names></name><name><surname>Cinatl</surname><given-names>J.</given-names></name><name><surname>Doerr</surname><given-names>H.</given-names></name></person-group><article-title>Efficacy of various disinfectants against SARS coronavirus</article-title><source>J. Hosp. Infect.</source><year>2005</year><volume>61</volume><fpage>107</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/j.jhin.2004.12.023</pub-id><pub-id pub-id-type="pmid">15923059</pub-id></element-citation></ref><ref id="B19-jcm-09-02441"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kampf</surname><given-names>G.</given-names></name><name><surname>Todt</surname><given-names>D.</given-names></name><name><surname>Pfaender</surname><given-names>S.</given-names></name><name><surname>Steinmann</surname><given-names>E.</given-names></name></person-group><article-title>Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents</article-title><source>J. Hosp. Infect.</source><year>2020</year><volume>104</volume><fpage>246</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1016/j.jhin.2020.01.022</pub-id><pub-id pub-id-type="pmid">32035997</pub-id></element-citation></ref><ref id="B20-jcm-09-02441"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sizun</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>M.</given-names></name><name><surname>Talbot</surname><given-names>P.</given-names></name></person-group><article-title>Survival of human coronaviruses 229E and OC43 in suspension and after drying onsurfaces: A possible source ofhospital-acquired infections</article-title><source>J. Hosp. Infect.</source><year>2000</year><volume>46</volume><fpage>55</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1053/jhin.2000.0795</pub-id><pub-id pub-id-type="pmid">11023724</pub-id></element-citation></ref><ref id="B21-jcm-09-02441"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kariwa</surname><given-names>H.</given-names></name><name><surname>Fujii</surname><given-names>N.</given-names></name><name><surname>Takashima</surname><given-names>I.</given-names></name></person-group><article-title>Inactivation of SARS Coronavirus by Means of Povidone-Iodine, Physical Conditions and Chemical Reagents</article-title><source>Dermatology</source><year>2006</year><volume>212</volume><fpage>119</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1159/000089211</pub-id><pub-id pub-id-type="pmid">16490989</pub-id></element-citation></ref><ref id="B22-jcm-09-02441"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C.-J.</given-names></name><name><surname>Ding</surname><given-names>S.-J.</given-names></name></person-group><article-title>Effectiveness of Hypochlorous Acid to Reduce the Biofilms on Titanium Alloy Surfaces in Vitro</article-title><source>Int. J. Mol. Sci.</source><year>2016</year><volume>17</volume><elocation-id>1161</elocation-id><pub-id pub-id-type="doi">10.3390/ijms17071161</pub-id><?supplied-pmid 27447617?><pub-id pub-id-type="pmid">27447617</pub-id></element-citation></ref><ref id="B23-jcm-09-02441"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cermelli</surname><given-names>C.</given-names></name><name><surname>Cuoghi</surname><given-names>A.</given-names></name><name><surname>Scuri</surname><given-names>M.</given-names></name><name><surname>Bettua</surname><given-names>C.</given-names></name><name><surname>Neglia</surname><given-names>R.G.</given-names></name><name><surname>Ardizzoni</surname><given-names>A.</given-names></name><name><surname>Blasi</surname><given-names>E.</given-names></name><name><surname>Iannitti</surname><given-names>T.</given-names></name><name><surname>Palmieri</surname><given-names>B.</given-names></name></person-group><article-title>In vitro evaluation of antiviral and virucidal activity of a high molecular weight hyaluronic acid</article-title><source>Virol. J.</source><year>2011</year><volume>8</volume><fpage>141</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-8-141</pub-id><?supplied-pmid 21439070?><pub-id pub-id-type="pmid">21439070</pub-id></element-citation></ref><ref id="B24-jcm-09-02441"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guillemard</surname><given-names>E.</given-names></name><name><surname>Geniteau-Legendre</surname><given-names>M.</given-names></name><name><surname>Mabboux</surname><given-names>B.</given-names></name><name><surname>Poilane</surname><given-names>I.</given-names></name><name><surname>Kergot</surname><given-names>R.</given-names></name><name><surname>Lemaire</surname><given-names>G.</given-names></name><name><surname>Petit</surname><given-names>J.</given-names></name><name><surname>Labarre</surname><given-names>C.</given-names></name><name><surname>Quero</surname><given-names>A.</given-names></name></person-group><article-title>Antiviral action of trehalose dimycolate against EMC virus: Role of macrophages and interferon &#x003b1;/&#x003b2;</article-title><source>Antivir. Res.</source><year>1993</year><volume>22</volume><fpage>201</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1016/0166-3542(93)90096-2</pub-id><pub-id pub-id-type="pmid">7506511</pub-id></element-citation></ref><ref id="B25-jcm-09-02441"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guillemard</surname><given-names>E.</given-names></name><name><surname>Geniteau-Legendre</surname><given-names>M.</given-names></name><name><surname>Kergot</surname><given-names>R.</given-names></name><name><surname>Lemaire</surname><given-names>G.</given-names></name><name><surname>Petit</surname><given-names>J.</given-names></name><name><surname>Labarre</surname><given-names>C.</given-names></name><name><surname>Quero</surname><given-names>A.</given-names></name></person-group><article-title>Role of trehalose dimycolate-induced interferon-&#x003b1;/&#x003b2; in the restriction of encephalomyocarditis virus growth in vivo and in peritoneal macrophage cultures</article-title><source>Antivir. Res.</source><year>1995</year><volume>28</volume><fpage>175</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/0166-3542(95)00047-P</pub-id><pub-id pub-id-type="pmid">8585770</pub-id></element-citation></ref><ref id="B26-jcm-09-02441"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Clercq</surname><given-names>E.</given-names></name><name><surname>Luczak</surname><given-names>M.</given-names></name></person-group><article-title>Antiviral activity of carbopol, a cross-linked polycarboxylate</article-title><source>Arch. Virol.</source><year>1976</year><volume>52</volume><fpage>151</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1007/BF01317874</pub-id><pub-id pub-id-type="pmid">187146</pub-id></element-citation></ref><ref id="B27-jcm-09-02441"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harmsen</surname><given-names>M.C.</given-names></name><name><surname>Swart</surname><given-names>P.J.</given-names></name><name><surname>Bethune</surname><given-names>M.-P.D.</given-names></name><name><surname>Pauwels</surname><given-names>R.</given-names></name><name><surname>Clercq</surname><given-names>E.D.</given-names></name><name><surname>The</surname><given-names>T.B.</given-names></name><name><surname>Meijer</surname><given-names>D.K.F.</given-names></name></person-group><article-title>Antiviral Effects of Plasma and Milk Proteins: Lactoferrin Shows Potent Activity against Both Human Immunodeficiency Virus and Human Cytomegalovirus Replication In Vitro</article-title><source>J. Infect. Dis.</source><year>1995</year><volume>172</volume><fpage>380</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1093/infdis/172.2.380</pub-id><pub-id pub-id-type="pmid">7622881</pub-id></element-citation></ref><ref id="B28-jcm-09-02441"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Der Strate</surname><given-names>B.W.</given-names></name><name><surname>Beljaars</surname><given-names>L.</given-names></name><name><surname>Molema</surname><given-names>G.</given-names></name><name><surname>Harmsen</surname><given-names>M.C.</given-names></name><name><surname>Meijer</surname><given-names>D.</given-names></name></person-group><article-title>Antiviral activities of lactoferrin</article-title><source>Antivir. Res.</source><year>2001</year><volume>52</volume><fpage>225</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/S0166-3542(01)00195-4</pub-id><pub-id pub-id-type="pmid">11675140</pub-id></element-citation></ref><ref id="B29-jcm-09-02441"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>C.</given-names></name><name><surname>Reichling</surname><given-names>J.</given-names></name><name><surname>Schneele</surname><given-names>J.</given-names></name><name><surname>Schnitzler</surname><given-names>P.</given-names></name></person-group><article-title>Inhibitory effect of essential oils against herpes simplex virus type 2</article-title><source>Phytomedicine</source><year>2008</year><volume>15</volume><fpage>71</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2007.09.003</pub-id><pub-id pub-id-type="pmid">17976968</pub-id></element-citation></ref><ref id="B30-jcm-09-02441"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>C.</given-names></name><name><surname>Reichling</surname><given-names>J.</given-names></name><name><surname>Kehm</surname><given-names>R.</given-names></name><name><surname>Sharaf</surname><given-names>M.M.</given-names></name><name><surname>Zentgraf</surname><given-names>H.</given-names></name><name><surname>Schneele</surname><given-names>J.</given-names></name><name><surname>Schnitzler</surname><given-names>P.</given-names></name></person-group><article-title>Efficacy of anise oil, dwarf-pine oil and chamomile oil against thymidine-kinase-positive and thymidine-kinase-negative herpes viruses</article-title><source>J. Pharm. Pharmacol.</source><year>2008</year><volume>60</volume><fpage>1545</fpage><lpage>1550</lpage><pub-id pub-id-type="doi">10.1211/jpp.60.11.0017</pub-id><pub-id pub-id-type="pmid">18957177</pub-id></element-citation></ref><ref id="B31-jcm-09-02441"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Binns</surname><given-names>S.E.</given-names></name><name><surname>Merali</surname><given-names>S.</given-names></name><name><surname>Hudson</surname><given-names>J.</given-names></name><name><surname>Arnason</surname><given-names>J.T.</given-names></name></person-group><article-title>Antiviral Activity of Characterized Extracts from Echinacea spp. (Heliantheae: Asteraceae) against Herpes simplex Virus (HSV-I)</article-title><source>Planta Med.</source><year>2002</year><volume>68</volume><fpage>780</fpage><lpage>783</lpage><pub-id pub-id-type="doi">10.1055/s-2002-34397</pub-id><pub-id pub-id-type="pmid">12357386</pub-id></element-citation></ref><ref id="B32-jcm-09-02441"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danaher</surname><given-names>R.J.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Dai</surname><given-names>J.</given-names></name><name><surname>Mumper</surname><given-names>R.J.</given-names></name><name><surname>Miller</surname><given-names>C.S.</given-names></name></person-group><article-title>Antiviral effects of blackberry extract against herpes simplex virus type 1</article-title><source>Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontol.</source><year>2011</year><volume>112</volume><fpage>e31</fpage><lpage>e35</lpage><pub-id pub-id-type="doi">10.1016/j.tripleo.2011.04.007</pub-id><?supplied-pmid 21827957?><pub-id pub-id-type="pmid">21827957</pub-id></element-citation></ref><ref id="B33-jcm-09-02441"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>L.-T.</given-names></name><name><surname>Hsu</surname><given-names>W.-C.</given-names></name><name><surname>Lin</surname><given-names>C.-C.</given-names></name></person-group><article-title>Antiviral Natural Products and Herbal Medicines</article-title><source>J. Tradit. Complement. Med.</source><year>2014</year><volume>4</volume><fpage>24</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.4103/2225-4110.124335</pub-id><?supplied-pmid 24872930?><pub-id pub-id-type="pmid">24872930</pub-id></element-citation></ref><ref id="B34-jcm-09-02441"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.-Z.</given-names></name><name><surname>Li</surname><given-names>W.-J.</given-names></name><name><surname>Tao</surname><given-names>R.</given-names></name><name><surname>Ye</surname><given-names>J.-Z.</given-names></name><name><surname>Zhang</surname><given-names>H.-Y.</given-names></name></person-group><article-title>Antiviral Activity of a Nanoemulsion of Polyprenols from Ginkgo Leaves against Influenza A H3N2 and Hepatitis B Virus in Vitro</article-title><source>Molecules</source><year>2015</year><volume>20</volume><fpage>5137</fpage><lpage>5151</lpage><pub-id pub-id-type="doi">10.3390/molecules20035137</pub-id><pub-id pub-id-type="pmid">25808155</pub-id></element-citation></ref><ref id="B35-jcm-09-02441"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J.-H.</given-names></name><name><surname>Park</surname><given-names>J.-S.</given-names></name><name><surname>Lee</surname><given-names>S.-W.</given-names></name><name><surname>Hwang</surname><given-names>S.-Y.</given-names></name><name><surname>Young</surname><given-names>B.-E.</given-names></name><name><surname>Choi</surname><given-names>H.-J.</given-names></name></person-group><article-title>Porcine epidemic diarrhea virus infection: Inhibition by polysaccharide from Ginkgo biloba exocarp and mode of its action</article-title><source>Virus Res.</source><year>2015</year><volume>195</volume><fpage>148</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2014.09.013</pub-id><pub-id pub-id-type="pmid">25300802</pub-id></element-citation></ref><ref id="B36-jcm-09-02441"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamidi</surname><given-names>J.A.</given-names></name><name><surname>Ismaili</surname><given-names>N.H.</given-names></name><name><surname>Ahmadi</surname><given-names>F.B.</given-names></name><name><surname>Lajisi</surname><given-names>N.H.</given-names></name></person-group><article-title>Antiviral and cytotoxic activities of some plants used in Malaysian indigenous medicine</article-title><source>Pertanika J. Trop. Agric. Sci.</source><year>1996</year><volume>19</volume><fpage>129</fpage><lpage>136</lpage></element-citation></ref><ref id="B37-jcm-09-02441"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tharanath</surname><given-names>V.</given-names></name><name><surname>Peddanna</surname><given-names>K.</given-names></name><name><surname>Kotaiah</surname><given-names>Y.</given-names></name><name><surname>Venkataramana</surname><given-names>D.</given-names></name></person-group><article-title>Flavonoids isolated from Foeniculum vulgare (Fennel) have virostatic efficiency against bluetongue virus</article-title><source>Int. J. Pharm. Sci. Rev. Res.</source><year>2013</year><volume>23</volume><fpage>237</fpage><lpage>242</lpage></element-citation></ref><ref id="B38-jcm-09-02441"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reichling</surname><given-names>J.</given-names></name><name><surname>Schnitzler</surname><given-names>P.</given-names></name><name><surname>Suschke</surname><given-names>U.</given-names></name><name><surname>Saller</surname><given-names>R.</given-names></name></person-group><article-title>Essential Oils of Aromatic Plants with Antibacterial, Antifungal, Antiviral, and Cytotoxic Properties&#x02014;An Overview</article-title><source>Complement. Med. Res.</source><year>2009</year><volume>16</volume><fpage>79</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1159/000207196</pub-id></element-citation></ref><ref id="B39-jcm-09-02441"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Clercq</surname><given-names>E.</given-names></name></person-group><article-title>Potential antivirals and antiviral strategies against SARS coronavirus infections</article-title><source>Expert Rev. Anti-Infect. Ther.</source><year>2014</year><volume>4</volume><fpage>291</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1586/14787210.4.2.291</pub-id></element-citation></ref><ref id="B40-jcm-09-02441"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welch</surname><given-names>J.L.</given-names></name><name><surname>Xiang</surname><given-names>J.</given-names></name><name><surname>Okeoma</surname><given-names>C.M.</given-names></name><name><surname>Schlievert</surname><given-names>P.M.</given-names></name><name><surname>Stapleton</surname><given-names>J.T.</given-names></name></person-group><article-title>Glycerol Monolaurate, an Analogue to a Factor Secreted by Lactobacillus, Is Virucidal against Enveloped Viruses, Including HIV-1</article-title><source>mBio</source><year>2020</year><volume>11</volume><pub-id pub-id-type="doi">10.1128/mBio.00686-20</pub-id></element-citation></ref><ref id="B41-jcm-09-02441"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patrick</surname><given-names>L.</given-names></name></person-group><article-title>N-acetylcysteine, Alpha-Lipoic Acid, L-Glutamine, and L-Carnitine</article-title><source>Altern. Med. Rev.</source><year>2000</year><volume>5</volume><fpage>290</fpage><pub-id pub-id-type="pmid">10956377</pub-id></element-citation></ref><ref id="B42-jcm-09-02441"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Travagli</surname><given-names>V.</given-names></name><name><surname>Zanardi</surname><given-names>I.</given-names></name><name><surname>Bocci</surname><given-names>V.</given-names></name></person-group><article-title>Topical applications of ozone and ozonated oils as anti-infective agents: An insight into the patent claims</article-title><source>Recent Pat. Anti-Infect. Drug Discov.</source><year>2009</year><volume>4</volume><fpage>130</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.2174/157489109788490271</pub-id><?supplied-pmid 19519548?><pub-id pub-id-type="pmid">19519548</pub-id></element-citation></ref><ref id="B43-jcm-09-02441"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ugazio</surname><given-names>E.</given-names></name><name><surname>Tullio</surname><given-names>V.</given-names></name><name><surname>Binello</surname><given-names>A.</given-names></name><name><surname>Tagliapietra</surname><given-names>S.</given-names></name><name><surname>Dosio</surname><given-names>F.</given-names></name></person-group><article-title>Ozonated Oils as Antimicrobial Systems in Topical Applications. Their Characterization, Current Applications, and Advances in Improved Delivery Techniques</article-title><source>Molecules</source><year>2020</year><volume>25</volume><elocation-id>334</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25020334</pub-id><?supplied-pmid 31947580?><pub-id pub-id-type="pmid">31947580</pub-id></element-citation></ref><ref id="B44-jcm-09-02441"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowen</surname><given-names>R.J.</given-names></name><name><surname>Robins</surname><given-names>H.</given-names></name></person-group><article-title>A Plausible &#x0201c;Penny&#x0201d; Costing Effective Treatment for Corona Virus Ozone Therapy</article-title><source>J. Infect. Dis. Epidemiol.</source><year>2020</year><volume>6</volume><fpage>113</fpage></element-citation></ref><ref id="B45-jcm-09-02441"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Ko</surname><given-names>G.</given-names></name></person-group><article-title>Antiviral effect of vitamin A on norovirus infection via modulation of the gut microbiome</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>25835</fpage><pub-id pub-id-type="doi">10.1038/srep25835</pub-id><?supplied-pmid 27180604?><pub-id pub-id-type="pmid">27180604</pub-id></element-citation></ref><ref id="B46-jcm-09-02441"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koyama</surname><given-names>A.H.</given-names></name><name><surname>Furuya</surname><given-names>A.</given-names></name><name><surname>Uozaki</surname><given-names>M.</given-names></name><name><surname>Yamasaki</surname><given-names>H.</given-names></name><name><surname>Arakawa</surname><given-names>T.</given-names></name><name><surname>Arita</surname><given-names>M.</given-names></name></person-group><article-title>Antiviral effects of ascorbic and dehydroascorbic acids in vitro</article-title><source>Int. J. Mol. Med.</source><year>1998</year><volume>22</volume><fpage>541</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.3892/ijmm_00000053</pub-id></element-citation></ref><ref id="B47-jcm-09-02441"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brinkevich</surname><given-names>S.D.</given-names></name><name><surname>Boreko</surname><given-names>E.</given-names></name><name><surname>Savinova</surname><given-names>O.V.</given-names></name><name><surname>Pavlova</surname><given-names>N.I.</given-names></name><name><surname>Shadyro</surname><given-names>O.I.</given-names></name></person-group><article-title>Radical-regulating and antiviral properties of ascorbic acid and its derivatives</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2012</year><volume>22</volume><fpage>2424</fpage><lpage>2427</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2012.02.022</pub-id><pub-id pub-id-type="pmid">22390834</pub-id></element-citation></ref><ref id="B48-jcm-09-02441"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hovi</surname><given-names>T.</given-names></name><name><surname>Hirvimies</surname><given-names>A.</given-names></name><name><surname>Stenvik</surname><given-names>M.</given-names></name><name><surname>Vuola</surname><given-names>E.</given-names></name><name><surname>Pippuri</surname><given-names>R.</given-names></name></person-group><article-title>Topical treatment of recurrent mucocutaneous herpes with ascorbic acid-containing solution</article-title><source>Antivir. Res.</source><year>1995</year><volume>27</volume><fpage>263</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1016/0166-3542(95)00010-J</pub-id><pub-id pub-id-type="pmid">8540748</pub-id></element-citation></ref><ref id="B49-jcm-09-02441"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bitetto</surname><given-names>D.</given-names></name><name><surname>Fabris</surname><given-names>C.</given-names></name><name><surname>Fornasiere</surname><given-names>E.</given-names></name><name><surname>Pipan</surname><given-names>C.</given-names></name><name><surname>Fumolo</surname><given-names>E.</given-names></name><name><surname>Cussigh</surname><given-names>A.</given-names></name><name><surname>Bignulin</surname><given-names>S.</given-names></name><name><surname>Cmet</surname><given-names>S.</given-names></name><name><surname>Fontanini</surname><given-names>E.</given-names></name><name><surname>Falleti</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C</article-title><source>Transpl. Int.</source><year>2010</year><volume>24</volume><fpage>43</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1111/j.1432-2277.2010.01141.x</pub-id></element-citation></ref><ref id="B50-jcm-09-02441"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gal-Tanamy</surname><given-names>M.</given-names></name><name><surname>Bachmetov</surname><given-names>L.</given-names></name><name><surname>Ravid</surname><given-names>A.</given-names></name><name><surname>Koren</surname><given-names>R.</given-names></name><name><surname>Erman</surname><given-names>A.</given-names></name><name><surname>Tur-Kaspa</surname><given-names>R.</given-names></name><name><surname>Zemel</surname><given-names>R.</given-names></name></person-group><article-title>Vitamin D: An innate antiviral agent suppressing hepatitis C virus in human hepatocytes</article-title><source>Hepatology</source><year>2011</year><volume>54</volume><fpage>1570</fpage><lpage>1579</lpage><pub-id pub-id-type="doi">10.1002/hep.24575</pub-id><pub-id pub-id-type="pmid">21793032</pub-id></element-citation></ref><ref id="B51-jcm-09-02441"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hubbard</surname><given-names>G.B.</given-names></name><name><surname>Herron</surname><given-names>B.E.</given-names></name><name><surname>Andrews</surname><given-names>J.S.</given-names></name><name><surname>Elliott</surname><given-names>J.H.</given-names></name></person-group><article-title>Influence of topical and oral zinc upon corneal wound healing</article-title><source>Br. J. Ophthalmol.</source><year>1969</year><volume>53</volume><fpage>407</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1136/bjo.53.6.407</pub-id><pub-id pub-id-type="pmid">5794958</pub-id></element-citation></ref><ref id="B52-jcm-09-02441"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Titiyal</surname><given-names>J.S.</given-names></name><name><surname>Kaur</surname><given-names>M.</given-names></name><name><surname>Falera</surname><given-names>R.</given-names></name><name><surname>Bharghava</surname><given-names>A.</given-names></name><name><surname>Sah</surname><given-names>R.</given-names></name><name><surname>Sen</surname><given-names>S.</given-names></name></person-group><article-title>Efficacy and Safety of Topical Chloroquine in Mild to Moderate Dry Eye Disease</article-title><source>Curr. Eye Res.</source><year>2019</year><volume>44</volume><fpage>1306</fpage><lpage>1312</lpage><pub-id pub-id-type="doi">10.1080/02713683.2019.1641824</pub-id><?supplied-pmid 31283891?><pub-id pub-id-type="pmid">31283891</pub-id></element-citation></ref><ref id="B53-jcm-09-02441"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wand</surname><given-names>M.</given-names></name><name><surname>Gilbert</surname><given-names>C.M.</given-names></name><name><surname>Liesegang</surname><given-names>T.J.</given-names></name></person-group><article-title>Latanoprost and herpes simplex keratitis</article-title><source>Am. J. Ophthalmol.</source><year>1999</year><volume>127</volume><fpage>602</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1016/S0002-9394(99)00050-1</pub-id><pub-id pub-id-type="pmid">10334356</pub-id></element-citation></ref><ref id="B54-jcm-09-02441"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname><given-names>H.E.</given-names></name><name><surname>Varnell</surname><given-names>E.D.</given-names></name><name><surname>Thompson</surname><given-names>H.W.</given-names></name></person-group><article-title>Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit</article-title><source>Am. J. Ophthalmol.</source><year>1999</year><volume>127</volume><fpage>531</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1016/S0002-9394(99)00089-6</pub-id><pub-id pub-id-type="pmid">10334345</pub-id></element-citation></ref><ref id="B55-jcm-09-02441"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>H.G.</given-names></name><name><surname>Choi</surname><given-names>S.</given-names></name></person-group><article-title>A Case of Herpetic Simplex Keratitis after Application of 0.015% Tafluprost Eye Drops</article-title><source>J. Korean Ophthalmol. Soc.</source><year>2013</year><volume>54</volume><fpage>1950</fpage><pub-id pub-id-type="doi">10.3341/jkos.2013.54.12.1950</pub-id></element-citation></ref><ref id="B56-jcm-09-02441"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kroll</surname><given-names>D.M.</given-names></name><name><surname>Schuman</surname><given-names>J.S.</given-names></name></person-group><article-title>Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma</article-title><source>Am. J. Ophthalmol.</source><year>2002</year><volume>133</volume><fpage>401</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1016/S0002-9394(01)01360-5</pub-id><pub-id pub-id-type="pmid">11860979</pub-id></element-citation></ref><ref id="B57-jcm-09-02441"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H.S.</given-names></name><name><surname>Park</surname><given-names>H.G.</given-names></name><name><surname>Choi</surname><given-names>S.</given-names></name></person-group><article-title>Reactivation of Herpetic Keratitis in a Patient after Using Two Different Prostaglandin Analogues</article-title><source>J. Korean Ophthalmol. Soc.</source><year>2011</year><volume>52</volume><fpage>1119</fpage><pub-id pub-id-type="doi">10.3341/jkos.2011.52.9.1119</pub-id></element-citation></ref><ref id="B58-jcm-09-02441"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shanmugam</surname><given-names>S.</given-names></name><name><surname>Vetrichelvan</surname><given-names>T.</given-names></name></person-group><article-title>Formulation Development and Evaluation of OpthalmicOcusert Containing Timolol Maleate</article-title><source>Res. Rev. A J. Drug Formul. Dev. Prod.</source><year>2017</year><volume>4</volume><fpage>8</fpage><lpage>12</lpage></element-citation></ref><ref id="B59-jcm-09-02441"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>J.</given-names></name><name><surname>Marathe</surname><given-names>B.</given-names></name><name><surname>Govorkova</surname><given-names>E.A.</given-names></name><name><surname>Zheng</surname><given-names>J.J.</given-names></name></person-group><article-title>Drug Repurposing Identifies Inhibitors of Oseltamivir-Resistant Influenza Viruses</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2016</year><volume>55</volume><fpage>3438</fpage><lpage>3441</lpage><pub-id pub-id-type="doi">10.1002/anie.201511361</pub-id><pub-id pub-id-type="pmid">26833677</pub-id></element-citation></ref><ref id="B60-jcm-09-02441"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Josset</surname><given-names>L.</given-names></name><name><surname>Textoris</surname><given-names>J.</given-names></name><name><surname>Loriod</surname><given-names>B.</given-names></name><name><surname>Ferraris</surname><given-names>O.</given-names></name><name><surname>Moules</surname><given-names>V.</given-names></name><name><surname>Lina</surname><given-names>B.</given-names></name><name><surname>N&#x02019;Guyen</surname><given-names>C.</given-names></name><name><surname>Diaz</surname><given-names>J.-J.</given-names></name><name><surname>Rosa-Calatrava</surname><given-names>M.</given-names></name></person-group><article-title>Gene Expression Signature-Based Screening Identifies New Broadly Effective Influenza A Antivirals</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><elocation-id>e13169</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0013169</pub-id><pub-id pub-id-type="pmid">20957181</pub-id></element-citation></ref><ref id="B61-jcm-09-02441"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juurlink</surname><given-names>D.N.</given-names></name></person-group><article-title>Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection</article-title><source>Can. Med. Assoc. J.</source><year>2020</year><volume>192</volume><fpage>E450</fpage><lpage>E453</lpage><pub-id pub-id-type="doi">10.1503/cmaj.200528</pub-id><pub-id pub-id-type="pmid">32269021</pub-id></element-citation></ref><ref id="B62-jcm-09-02441"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sodhi</surname><given-names>M.</given-names></name><name><surname>Etminan</surname><given-names>M.</given-names></name></person-group><article-title>Therapeutic Potential for Tetracyclines in the Treatment of COVID-19</article-title><source>Pharmacother. J. Hum. Pharmacol. Drug Ther.</source><year>2020</year><volume>40</volume><fpage>487</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1002/phar.2395</pub-id><?supplied-pmid 32267566?><pub-id pub-id-type="pmid">32267566</pub-id></element-citation></ref><ref id="B63-jcm-09-02441"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enoki</surname><given-names>Y.</given-names></name><name><surname>Ishima</surname><given-names>Y.</given-names></name><name><surname>Tanaka</surname><given-names>R.</given-names></name><name><surname>Sato</surname><given-names>K.</given-names></name><name><surname>Kimachi</surname><given-names>K.</given-names></name><name><surname>Shirai</surname><given-names>T.</given-names></name><name><surname>Watanabe</surname><given-names>H.</given-names></name><name><surname>Chuang</surname><given-names>V.T.G.</given-names></name><name><surname>Fujiwara</surname><given-names>Y.</given-names></name><name><surname>Takeya</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Pleiotropic Effects of Levofloxacin, Fluoroquinolone Antibiotics, against Influenza Virus-Induced Lung Injury</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0130248</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0130248</pub-id><?supplied-pmid 26086073?><pub-id pub-id-type="pmid">26086073</pub-id></element-citation></ref><ref id="B64-jcm-09-02441"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knoll</surname><given-names>G.A.</given-names></name><name><surname>Humar</surname><given-names>A.</given-names></name><name><surname>Fergusson</surname><given-names>D.</given-names></name><name><surname>Johnston</surname><given-names>O.</given-names></name><name><surname>House</surname><given-names>A.A.</given-names></name><name><surname>Kim</surname><given-names>S.J.</given-names></name><name><surname>Ramsay</surname><given-names>T.</given-names></name><name><surname>Chass&#x000e9;</surname><given-names>M.</given-names></name><name><surname>Pang</surname><given-names>X.</given-names></name><name><surname>Zaltzman</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Levofloxacin for BK Virus Prophylaxis Following Kidney Transplantation</article-title><source>JAMA</source><year>2014</year><volume>312</volume><fpage>2106</fpage><pub-id pub-id-type="doi">10.1001/jama.2014.14721</pub-id><pub-id pub-id-type="pmid">25399012</pub-id></element-citation></ref><ref id="B65-jcm-09-02441"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Lee</surname><given-names>M.-K.</given-names></name><name><surname>Ko</surname><given-names>J.</given-names></name><name><surname>Park</surname><given-names>C.-J.</given-names></name><name><surname>Kim</surname><given-names>M.</given-names></name><name><surname>Jeong</surname><given-names>Y.</given-names></name><name><surname>Hong</surname><given-names>S.</given-names></name><name><surname>Varani</surname><given-names>G.</given-names></name><name><surname>Choi</surname><given-names>B.-S.</given-names></name></person-group><article-title>Aminoglycoside antibiotics bind to the influenza a virus RNA promoter</article-title><source>Mol. BioSyst.</source><year>2012</year><volume>8</volume><fpage>2857</fpage><lpage>2859</lpage><pub-id pub-id-type="doi">10.1039/c2mb25333j</pub-id><pub-id pub-id-type="pmid">22990985</pub-id></element-citation></ref><ref id="B66-jcm-09-02441"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Topno</surname><given-names>R.</given-names></name><name><surname>Khan</surname><given-names>S.A.</given-names></name><name><surname>Chowdhury</surname><given-names>P.</given-names></name><name><surname>Mahanta</surname><given-names>J.</given-names></name></person-group><article-title>Pharmacodynamics of aminoglycosides and tetracycline derivatives against Japanese encephalitis virus</article-title><source>Asian Pac. J. Trop. Med.</source><year>2016</year><volume>9</volume><fpage>241</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1016/j.apjtm.2016.01.033</pub-id><?supplied-pmid 26972394?><pub-id pub-id-type="pmid">26972394</pub-id></element-citation></ref><ref id="B67-jcm-09-02441"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zegarelli</surname><given-names>E.V.</given-names></name><name><surname>Budowsky</surname><given-names>J.</given-names></name><name><surname>Silvers</surname><given-names>H.F.</given-names></name><name><surname>Kutscher</surname><given-names>A.H.</given-names></name></person-group><article-title>Chloramphenicol in Treatment of Primary Herpetic Stomatitis And Herpes Labialis</article-title><source>Arch. Dermatol.</source><year>1953</year><volume>67</volume><fpage>635</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1001/archderm.1953.01540060097019</pub-id><?supplied-pmid 13050191?><pub-id pub-id-type="pmid">13050191</pub-id></element-citation></ref><ref id="B68-jcm-09-02441"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>David</surname><given-names>H.L.</given-names></name><name><surname>Rastogi</surname><given-names>N.</given-names></name><name><surname>Clavel-S&#x000e9;r&#x000e8;s</surname><given-names>S.</given-names></name><name><surname>Cl&#x000e9;ment</surname><given-names>F.</given-names></name></person-group><article-title>Action of Colistin (Polymyxin E) on the Lytic Cycle of the Mycobacteriophage D29 in Mycobacterium tuberculosis</article-title><source>Zent. Bakteriol. Mikrobiol. Hyg. Ser. A Med. Microbiol. Infect. Dis. Virol. Parasitol.</source><year>1986</year><volume>262</volume><fpage>321</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1016/S0176-6724(86)80005-0</pub-id></element-citation></ref><ref id="B69-jcm-09-02441"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.F.-W.</given-names></name><name><surname>Ma</surname><given-names>M.K.-M.</given-names></name><name><surname>Chan</surname><given-names>G.S.-W.</given-names></name><name><surname>Chan</surname><given-names>G.C.-W.</given-names></name><name><surname>Choi</surname><given-names>G.K.-Y.</given-names></name><name><surname>Chan</surname><given-names>K.-H.</given-names></name><name><surname>Cheng</surname><given-names>V.C.-C.</given-names></name><name><surname>Choy</surname><given-names>B.-Y.</given-names></name><name><surname>Yuen</surname><given-names>K.-Y.</given-names></name><name><surname>Chan</surname><given-names>K.-W.</given-names></name></person-group><article-title>Rapid reduction of viruria and stabilization of allograft function by fusidic acid in a renal transplant recipient with JC virus-associated nephropathy</article-title><source>Infection</source><year>2015</year><volume>43</volume><fpage>577</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1007/s15010-015-0721-x</pub-id><pub-id pub-id-type="pmid">25944568</pub-id></element-citation></ref><ref id="B70-jcm-09-02441"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Famularo</surname><given-names>G.</given-names></name><name><surname>De Simone</surname><given-names>C.</given-names></name><name><surname>Tzantzoglou</surname><given-names>S.</given-names></name><name><surname>Trinchieri</surname><given-names>V.</given-names></name><name><surname>Moretti</surname><given-names>S.</given-names></name><name><surname>Tonietti</surname><given-names>G.</given-names></name></person-group><article-title>In Vivo and in Vitro Efficacy of Fusidic Acid in HIV Infection</article-title><source>Ann. N. Y. Acad. Sci.</source><year>1993</year><volume>685</volume><fpage>341</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.1993.tb35885.x</pub-id><pub-id pub-id-type="pmid">7689807</pub-id></element-citation></ref><ref id="B71-jcm-09-02441"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhoden</surname><given-names>E.</given-names></name><name><surname>Nix</surname><given-names>W.A.</given-names></name><name><surname>Weldon</surname><given-names>W.C.</given-names></name><name><surname>Selvarangan</surname><given-names>R.</given-names></name></person-group><article-title>Antifungal azoles itraconazole and posaconazole exhibit potent in vitro antiviral activity against clinical isolates of parechovirus A3 (Picornaviridae)</article-title><source>Antivir. Res.</source><year>2018</year><volume>149</volume><fpage>75</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2017.11.011</pub-id><pub-id pub-id-type="pmid">29155163</pub-id></element-citation></ref><ref id="B72-jcm-09-02441"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>G.W.</given-names></name><name><surname>Seet</surname><given-names>E.C.</given-names></name></person-group><article-title>Antiviral Effects of Amphotericin B Methyl Ester</article-title><source>Antimicrob. Agents Chemother.</source><year>1978</year><volume>13</volume><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1128/AAC.13.2.199</pub-id><?supplied-pmid 206201?><pub-id pub-id-type="pmid">206201</pub-id></element-citation></ref><ref id="B73-jcm-09-02441"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schloer</surname><given-names>S.</given-names></name><name><surname>Goretzko</surname><given-names>J.</given-names></name><name><surname>K&#x000fc;hnl</surname><given-names>A.</given-names></name><name><surname>Brunotte</surname><given-names>L.</given-names></name><name><surname>Ludwig</surname><given-names>S.</given-names></name><name><surname>Rescher</surname><given-names>U.</given-names></name></person-group><article-title>The clinically licensed antifungal drug itraconazole inhibits influenza virus in vitro and in vivo</article-title><source>Emerg. Microbes Infect.</source><year>2019</year><volume>8</volume><fpage>80</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1080/22221751.2018.1559709</pub-id><?supplied-pmid 30866762?><pub-id pub-id-type="pmid">30866762</pub-id></element-citation></ref><ref id="B74-jcm-09-02441"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takamura</surname><given-names>E.</given-names></name><name><surname>Uchio</surname><given-names>E.</given-names></name><name><surname>Ebihara</surname><given-names>N.</given-names></name><name><surname>Ohno</surname><given-names>S.</given-names></name><name><surname>Ohashi</surname><given-names>Y.</given-names></name><name><surname>Okamoto</surname><given-names>S.</given-names></name><name><surname>Kumagai</surname><given-names>N.</given-names></name><name><surname>Satake</surname><given-names>Y.</given-names></name><name><surname>Shoji</surname><given-names>J.</given-names></name><name><surname>Nakagawa</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Japanese guidelines for allergic conjunctival diseases 2017</article-title><source>Allergol. Int.</source><year>2017</year><volume>66</volume><fpage>220</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1016/j.alit.2016.12.004</pub-id><pub-id pub-id-type="pmid">28209324</pub-id></element-citation></ref><ref id="B75-jcm-09-02441"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonardi</surname><given-names>A.</given-names></name><name><surname>Bogacka</surname><given-names>E.</given-names></name><name><surname>Fauquert</surname><given-names>J.-L.</given-names></name><name><surname>Kowalski</surname><given-names>M.L.</given-names></name><name><surname>Groblewska</surname><given-names>A.</given-names></name><name><surname>Jedrzejczak-Czechowicz</surname><given-names>M.</given-names></name><name><surname>Doan</surname><given-names>S.</given-names></name><name><surname>Marmouz</surname><given-names>F.</given-names></name><name><surname>Demoly</surname><given-names>P.</given-names></name><name><surname>Delgado</surname><given-names>L.</given-names></name></person-group><article-title>Ocular allergy: Recognizing and diagnosing hypersensitivity disorders of the ocular surface</article-title><source>Allergy</source><year>2012</year><volume>67</volume><fpage>1327</fpage><lpage>1337</lpage><pub-id pub-id-type="doi">10.1111/all.12009</pub-id><?supplied-pmid 22947083?><pub-id pub-id-type="pmid">22947083</pub-id></element-citation></ref><ref id="B76-jcm-09-02441"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bron</surname><given-names>A.J.</given-names></name><name><surname>De Paiva</surname><given-names>C.S.</given-names></name><name><surname>Chauhan</surname><given-names>S.K.</given-names></name><name><surname>Bonini</surname><given-names>S.</given-names></name><name><surname>Gabison</surname><given-names>E.E.</given-names></name><name><surname>Jain</surname><given-names>S.</given-names></name><name><surname>Knop</surname><given-names>E.</given-names></name><name><surname>Markoulli</surname><given-names>M.</given-names></name><name><surname>Ogawa</surname><given-names>Y.</given-names></name><name><surname>Perez</surname><given-names>V.</given-names></name><etal/></person-group><article-title>TFOS DEWS II pathophysiology report</article-title><source>Ocul. Surf.</source><year>2017</year><volume>15</volume><fpage>438</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1016/j.jtos.2017.05.011</pub-id><?supplied-pmid 28736340?><pub-id pub-id-type="pmid">28736340</pub-id></element-citation></ref><ref id="B77-jcm-09-02441"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname><given-names>J.</given-names></name><name><surname>Gu</surname><given-names>J.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>J.-Q.</given-names></name></person-group><article-title>Tacrolimus in the Treatment of Ocular Diseases</article-title><source>BioDrugs</source><year>2011</year><volume>25</volume><fpage>89</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.2165/11587010-000000000-00000</pub-id><pub-id pub-id-type="pmid">21443273</pub-id></element-citation></ref><ref id="B78-jcm-09-02441"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>S.</given-names></name><name><surname>Lin</surname><given-names>B.</given-names></name><name><surname>Chu</surname><given-names>V.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>X.</given-names></name><name><surname>Xiao</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>A.Q.</given-names></name><name><surname>Schweitzer</surname><given-names>C.J.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Imamura</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection</article-title><source>Sci. Transl. Med.</source><year>2015</year><volume>7</volume><fpage>282ra49</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3010286</pub-id></element-citation></ref><ref id="B79-jcm-09-02441"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Xia</surname><given-names>S.</given-names></name><name><surname>Pu</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>P.</given-names></name><name><surname>Lu</surname><given-names>L.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>The Antihistamine Drugs Carbinoxamine Maleate and Chlorpheniramine Maleate Exhibit Potent Antiviral Activity against a Broad Spectrum of Influenza Viruses</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><pub-id pub-id-type="doi">10.3389/fmicb.2018.02643</pub-id></element-citation></ref><ref id="B80-jcm-09-02441"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schafer</surname><given-names>A.</given-names></name><name><surname>Cheng</surname><given-names>H.</given-names></name><name><surname>Xiong</surname><given-names>R.</given-names></name><name><surname>Soloveva</surname><given-names>V.</given-names></name><name><surname>Retterer</surname><given-names>C.</given-names></name><name><surname>Mo</surname><given-names>F.</given-names></name><name><surname>Bavari</surname><given-names>S.</given-names></name><name><surname>Thatcher</surname><given-names>G.</given-names></name><name><surname>Rong</surname><given-names>L.</given-names></name></person-group><article-title>Repurposing potential of 1st generation H 1 -specific antihistamines as anti-filovirus therapeutics</article-title><source>Antivir. Res.</source><year>2018</year><volume>157</volume><fpage>47</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2018.07.003</pub-id><pub-id pub-id-type="pmid">29981374</pub-id></element-citation></ref><ref id="B81-jcm-09-02441"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>J.W.</given-names></name><name><surname>Zahidi</surname><given-names>N.F.W.</given-names></name><name><surname>Kow</surname><given-names>A.S.F.</given-names></name><name><surname>Soo</surname><given-names>K.M.</given-names></name><name><surname>Shaari</surname><given-names>K.</given-names></name><name><surname>Israf</surname><given-names>D.A.</given-names></name><name><surname>Chee</surname><given-names>H.Y.</given-names></name><name><surname>Tham</surname><given-names>C.L.</given-names></name></person-group><article-title>Mast cell stabilizing effect of a geranyl acetophenone in dengue virus infection using in vitro model of DENV3-induced RBL-2H3 cells</article-title><source>Biosci. Rep.</source><year>2019</year><volume>39</volume><pub-id pub-id-type="doi">10.1042/BSR20181273</pub-id></element-citation></ref><ref id="B82-jcm-09-02441"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zawar</surname><given-names>V.P.</given-names></name><name><surname>Godse</surname><given-names>K.</given-names></name><name><surname>Sankalecha</surname><given-names>S.</given-names></name></person-group><article-title>Chronic urticaria associated with recurrent genital herpes simplex infection and success of antiviral therapy&#x02014;A report of two cases</article-title><source>Int. J. Infect. Dis.</source><year>2010</year><volume>14</volume><fpage>e514</fpage><lpage>e517</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2009.06.008</pub-id><?supplied-pmid 19699670?><pub-id pub-id-type="pmid">19699670</pub-id></element-citation></ref><ref id="B83-jcm-09-02441"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>S.-C.</given-names></name><name><surname>Chang</surname><given-names>Y.-S.</given-names></name><name><surname>Wang</surname><given-names>J.-P.</given-names></name><name><surname>Chen</surname><given-names>S.-C.</given-names></name><name><surname>Kuo</surname><given-names>S.-C.</given-names></name></person-group><article-title>Three New Flavonoids and Antiallergic, Anti-Inflammatory Constituents from the Heartwood of Dalbergia odorifera</article-title><source>Planta Med.</source><year>1998</year><volume>64</volume><fpage>153</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1055/s-2006-957394</pub-id><?supplied-pmid 9525107?><pub-id pub-id-type="pmid">9525107</pub-id></element-citation></ref><ref id="B84-jcm-09-02441"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaul</surname><given-names>T.N.</given-names></name><name><surname>Middleton</surname><given-names>E.</given-names></name><name><surname>Ogra</surname><given-names>P.L.</given-names></name></person-group><article-title>Antiviral effect of flavonoids on human viruses</article-title><source>J. Med. Virol.</source><year>1985</year><volume>15</volume><fpage>71</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1002/jmv.1890150110</pub-id><?supplied-pmid 2981979?><pub-id pub-id-type="pmid">2981979</pub-id></element-citation></ref><ref id="B85-jcm-09-02441"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabie</surname><given-names>R.</given-names></name><name><surname>Mumtaz</surname><given-names>K.</given-names></name><name><surname>Renner</surname><given-names>E.L.</given-names></name></person-group><article-title>Efficacy of antiviral therapy for hepatitis C after liver transplantation with cyclosporine and tacrolimus: A systematic review and meta-analysis</article-title><source>Liver Transplant.</source><year>2012</year><volume>19</volume><fpage>36</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1002/lt.23516</pub-id></element-citation></ref><ref id="B86-jcm-09-02441"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qing</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Zou</surname><given-names>G.</given-names></name><name><surname>Robida</surname><given-names>J.M.</given-names></name><name><surname>Yuan</surname><given-names>Z.</given-names></name><name><surname>Tang</surname><given-names>H.</given-names></name><name><surname>Shi</surname><given-names>P.-Y.</given-names></name></person-group><article-title>Cyclosporine Inhibits Flavivirus Replication through Blocking the Interaction between Host Cyclophilins and Viral NS5 Protein</article-title><source>Antimicrob. Agents Chemother.</source><year>2009</year><volume>53</volume><fpage>3226</fpage><lpage>3235</lpage><pub-id pub-id-type="doi">10.1128/AAC.00189-09</pub-id><pub-id pub-id-type="pmid">19451286</pub-id></element-citation></ref><ref id="B87-jcm-09-02441"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Musharrafieh</surname><given-names>R.G.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier of drug resistance</article-title><source>Antivir. Res.</source><year>2016</year><volume>133</volume><fpage>62</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2016.07.019</pub-id><pub-id pub-id-type="pmid">27478032</pub-id></element-citation></ref><ref id="B88-jcm-09-02441"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khyatti</surname><given-names>M.</given-names></name><name><surname>Menezes</surname><given-names>J.</given-names></name></person-group><article-title>The effect of indometacin, prostaglandin E2 and interferon on the multiplication of herpes simplex virus type 1 in human lymphoid cells</article-title><source>Antivir. Res.</source><year>1990</year><volume>14</volume><fpage>161</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/0166-3542(90)90032-3</pub-id><pub-id pub-id-type="pmid">1964373</pub-id></element-citation></ref><ref id="B89-jcm-09-02441"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higaki</surname><given-names>S.</given-names></name><name><surname>Watanabe</surname><given-names>K.</given-names></name><name><surname>Itahashi</surname><given-names>M.</given-names></name><name><surname>Shimomura</surname><given-names>Y.</given-names></name></person-group><article-title>Cyclooxygenase (COX)-Inhibiting Drug Reduces HSV-1 Reactivation in the Mouse Eye Model</article-title><source>Curr. Eye Res.</source><year>2009</year><volume>34</volume><fpage>171</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1080/02713680802650377</pub-id><pub-id pub-id-type="pmid">19274523</pub-id></element-citation></ref><ref id="B90-jcm-09-02441"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaye</surname><given-names>S.</given-names></name><name><surname>Choudhary</surname><given-names>A.</given-names></name></person-group><article-title>Herpes simplex keratitis</article-title><source>Prog. Retin. Eye Res.</source><year>2006</year><volume>25</volume><fpage>355</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1016/j.preteyeres.2006.05.001</pub-id><pub-id pub-id-type="pmid">16807055</pub-id></element-citation></ref><ref id="B91-jcm-09-02441"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkins</surname><given-names>M.R.</given-names></name><name><surname>Khan</surname><given-names>S.</given-names></name><name><surname>Bunce</surname><given-names>C.</given-names></name><name><surname>Khawaja</surname><given-names>A.P.</given-names></name><name><surname>Siriwardena</surname><given-names>D.</given-names></name><name><surname>Larkin</surname><given-names>D.F.P.</given-names></name></person-group><article-title>A randomised placebo-controlled trial of topical steroid in presumed viral conjunctivitis</article-title><source>Br. J. Ophthalmol.</source><year>2011</year><volume>95</volume><fpage>1299</fpage><lpage>1303</lpage><pub-id pub-id-type="doi">10.1136/bjo.2010.188623</pub-id><pub-id pub-id-type="pmid">21252084</pub-id></element-citation></ref><ref id="B92-jcm-09-02441"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>J.</given-names></name><name><surname>Mack</surname><given-names>H.G.</given-names></name></person-group><article-title>Management of conjunctivitis during the COVID-19 pandemic 2020</article-title><source>Aust. J. Gen. Pract.</source><year>2020</year><volume>49</volume><pub-id pub-id-type="doi">10.31128/AJGP-COVID-18</pub-id><?supplied-pmid 32362106?><pub-id pub-id-type="pmid">32362106</pub-id></element-citation></ref><ref id="B93-jcm-09-02441"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loffredo</surname><given-names>L.</given-names></name><name><surname>Pacella</surname><given-names>F.</given-names></name><name><surname>Pacella</surname><given-names>E.</given-names></name><name><surname>Tiscione</surname><given-names>G.</given-names></name><name><surname>Oliva</surname><given-names>A.</given-names></name><name><surname>Violi</surname><given-names>F.</given-names></name></person-group><article-title>Conjunctivitis and COVID-19: A meta-analysis</article-title><source>J. Med. Virol.</source><year>2020</year><pub-id pub-id-type="doi">10.1002/jmv.25938</pub-id><?supplied-pmid 32330304?><pub-id pub-id-type="pmid">32330304</pub-id></element-citation></ref><ref id="B94-jcm-09-02441"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Qiao</surname><given-names>K.</given-names></name><name><surname>Huang</surname><given-names>T.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Xin</surname><given-names>N.</given-names></name><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease</article-title><source>Br. J. Ophthalmol.</source><year>2020</year><volume>104</volume><fpage>748</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1136/bjophthalmol-2020-316304</pub-id><?supplied-pmid 32265202?><pub-id pub-id-type="pmid">32265202</pub-id></element-citation></ref><ref id="B95-jcm-09-02441"><label>95.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Solano</surname><given-names>D.</given-names></name><name><surname>Virgile</surname><given-names>J.</given-names></name><name><surname>Czyz</surname><given-names>C.N.</given-names></name></person-group><article-title>Viral Conjunctivitis</article-title><source>StatPearls</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2020</year></element-citation></ref><ref id="B96-jcm-09-02441"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skevaki</surname><given-names>C.L.</given-names></name><name><surname>Galani</surname><given-names>I.E.</given-names></name><name><surname>Pararas</surname><given-names>M.V.</given-names></name><name><surname>Giannopoulou</surname><given-names>K.P.</given-names></name><name><surname>Tsakris</surname><given-names>A.</given-names></name></person-group><article-title>Treatment of Viral Conjunctivitis with Antiviral Drugs</article-title><source>Drugs</source><year>2011</year><volume>71</volume><fpage>331</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.2165/11585330-000000000-00000</pub-id><?supplied-pmid 21319870?><pub-id pub-id-type="pmid">21319870</pub-id></element-citation></ref><ref id="B97-jcm-09-02441"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Zeng</surname><given-names>Y.</given-names></name><name><surname>Tong</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name></person-group><article-title>Ophthalmologic evidence against the interpersonal transmission of 2019 novel coronavirus through conjunctiva</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.02.11.20021956</pub-id></element-citation></ref><ref id="B98-jcm-09-02441"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colavita</surname><given-names>F.</given-names></name><name><surname>Lapa</surname><given-names>D.</given-names></name><name><surname>Carletti</surname><given-names>F.</given-names></name><name><surname>Lalle</surname><given-names>E.</given-names></name><name><surname>Bordi</surname><given-names>L.</given-names></name><name><surname>Marsella</surname><given-names>P.</given-names></name><name><surname>Nicastri</surname><given-names>E.</given-names></name><name><surname>Bevilacqua</surname><given-names>N.</given-names></name><name><surname>Giancola</surname><given-names>M.L.</given-names></name><name><surname>Corpolongo</surname><given-names>A.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 Isolation From Ocular Secretions of a Patient With COVID-19 in Italy With Prolonged Viral RNA Detection</article-title><source>Ann. Intern. Med.</source><year>2020</year><pub-id pub-id-type="doi">10.7326/M20-1176</pub-id></element-citation></ref><ref id="B99-jcm-09-02441"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Napoli</surname><given-names>P.E.</given-names></name><name><surname>Satta</surname><given-names>G.M.</given-names></name><name><surname>Coronella</surname><given-names>F.</given-names></name><name><surname>Fossarello</surname><given-names>M.</given-names></name></person-group><article-title>Spectral-Domain Optical Coherence Tomography Study on Dynamic Changes of Human Tears After Instillation of Artificial Tears</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2014</year><volume>55</volume><fpage>4533</fpage><lpage>4540</lpage><pub-id pub-id-type="doi">10.1167/iovs.14-14666</pub-id><pub-id pub-id-type="pmid">24985473</pub-id></element-citation></ref><ref id="B100-jcm-09-02441"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Napoli</surname><given-names>P.E.</given-names></name><name><surname>Coronella</surname><given-names>F.</given-names></name><name><surname>Satta</surname><given-names>G.M.</given-names></name><name><surname>Fossarello</surname><given-names>M.</given-names></name></person-group><article-title>A Novel Technique of Contrast-Enhanced Optical Coherence Tomography Imaging in Evaluation of Clearance of Lipids in Human Tears</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e109843</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0109843</pub-id><pub-id pub-id-type="pmid">25369027</pub-id></element-citation></ref><ref id="B101-jcm-09-02441"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Napoli</surname><given-names>P.E.</given-names></name><name><surname>Nioi</surname><given-names>M.</given-names></name><name><surname>Mangoni</surname><given-names>L.</given-names></name><name><surname>Gentile</surname><given-names>P.</given-names></name><name><surname>Braghiroli</surname><given-names>M.</given-names></name><name><surname>D&#x02019;Aloja</surname><given-names>E.</given-names></name><name><surname>Fossarello</surname><given-names>M.</given-names></name></person-group><article-title>Fourier-Domain OCT Imaging of the Ocular Surface and Tear Film Dynamics: A Review of the State of the Art and an Integrative Model of the Tear Behavior during the Inter-Blink Period and Visual Fixation</article-title><source>J. Clin. Med.</source><year>2020</year><volume>9</volume><elocation-id>668</elocation-id><pub-id pub-id-type="doi">10.3390/jcm9030668</pub-id></element-citation></ref><ref id="B102-jcm-09-02441"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Santvliet</surname><given-names>L.</given-names></name><name><surname>Ludwig</surname><given-names>A.</given-names></name></person-group><article-title>Determinants of eye drop size</article-title><source>Surv. Ophthalmol.</source><year>2004</year><volume>49</volume><fpage>197</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1016/j.survophthal.2003.12.009</pub-id><pub-id pub-id-type="pmid">14998692</pub-id></element-citation></ref><ref id="B103-jcm-09-02441"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodos</surname><given-names>R.A.</given-names></name><name><surname>Kidd</surname><given-names>B.A.</given-names></name><name><surname>Shameer</surname><given-names>K.</given-names></name><name><surname>Readhead</surname><given-names>B.P.</given-names></name><name><surname>Dudley</surname><given-names>J.T.</given-names></name><name><surname>Khader</surname><given-names>S.</given-names></name></person-group><article-title>In silico methods for drug repurposing and pharmacology</article-title><source>Wiley Interdiscip. Rev. Syst. Biol. Med.</source><year>2016</year><volume>8</volume><fpage>186</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1002/wsbm.1337</pub-id><?supplied-pmid 27080087?><pub-id pub-id-type="pmid">27080087</pub-id></element-citation></ref><ref id="B104-jcm-09-02441"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Xie</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>Review of Drug Repositioning Approaches and Resources</article-title><source>Int. J. Biol. Sci.</source><year>2018</year><volume>14</volume><fpage>1232</fpage><lpage>1244</lpage><pub-id pub-id-type="doi">10.7150/ijbs.24612</pub-id><?supplied-pmid 30123072?><pub-id pub-id-type="pmid">30123072</pub-id></element-citation></ref><ref id="B105-jcm-09-02441"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>J.</given-names></name></person-group><article-title>Can an anti-HIV combination or other existing drugs outwit the new coronavirus?</article-title><source>Science</source><year>2020</year><volume>10</volume><pub-id pub-id-type="doi">10.1126/science.abb0659</pub-id></element-citation></ref><ref id="B106-jcm-09-02441"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Peng</surname><given-names>G.</given-names></name><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Pennell</surname><given-names>C.A.</given-names></name><name><surname>Mansky</surname><given-names>L.M.</given-names></name><name><surname>Geraghty</surname><given-names>R.J.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>A Virus-Binding Hot Spot on Human Angiotensin-Converting Enzyme 2 Is Critical for Binding of Two Different Coronaviruses</article-title><source>J. Virol.</source><year>2011</year><volume>85</volume><fpage>5331</fpage><lpage>5337</lpage><pub-id pub-id-type="doi">10.1128/JVI.02274-10</pub-id><pub-id pub-id-type="pmid">21411533</pub-id></element-citation></ref><ref id="B107-jcm-09-02441"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>M.</given-names></name><name><surname>Baba</surname><given-names>M.</given-names></name><name><surname>Sato</surname><given-names>A.</given-names></name><name><surname>Pauwels</surname><given-names>R.</given-names></name><name><surname>De Clercq</surname><given-names>E.</given-names></name><name><surname>Shigeta</surname><given-names>S.</given-names></name></person-group><article-title>Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro</article-title><source>Antiviral Res.</source><year>1987</year><volume>7</volume><fpage>361</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1016/0166-3542(87)90018-0</pub-id><pub-id pub-id-type="pmid">2445284</pub-id></element-citation></ref><ref id="B108-jcm-09-02441"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.Y.</given-names></name><name><surname>Jin</surname><given-names>W.</given-names></name><name><surname>Sood</surname><given-names>A.</given-names></name><name><surname>Montgomery</surname><given-names>D.W.</given-names></name><name><surname>Grant</surname><given-names>O.C.</given-names></name><name><surname>Fuster</surname><given-names>M.M.</given-names></name><name><surname>Fu</surname><given-names>L.</given-names></name><name><surname>Dordick</surname><given-names>J.S.</given-names></name><name><surname>Woods</surname><given-names>R.J.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions</article-title><source>Antiviral Res.</source><year>2020</year><volume>10</volume><fpage>104873</fpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104873</pub-id></element-citation></ref><ref id="B109-jcm-09-02441"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnitzler</surname><given-names>P.</given-names></name><name><surname>Sch&#x000f6;n</surname><given-names>K.</given-names></name><name><surname>Reichling</surname><given-names>J.</given-names></name></person-group><article-title>Antiviral activity of Australian tea tree oil and eucalyptus oil against herpes simplex virus in cell culture</article-title><source>Die Pharm.</source><year>2001</year><volume>56</volume><fpage>343</fpage><lpage>347</lpage></element-citation></ref><ref id="B110-jcm-09-02441"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bishop</surname><given-names>C.D.</given-names></name></person-group><article-title>Antiviral Activity of the Essential Oil of Melaleuca alternifolia (Maiden amp; Betche) Cheel (Tea Tree) Against Tobacco Mosaic Virus</article-title><source>J. Essent. Oil Res.</source><year>1995</year><volume>7</volume><fpage>641</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1080/10412905.1995.9700519</pub-id></element-citation></ref><ref id="B111-jcm-09-02441"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garozzo</surname><given-names>A.</given-names></name><name><surname>Timpanaro</surname><given-names>R.</given-names></name><name><surname>Stivala</surname><given-names>A.</given-names></name><name><surname>Bisignano</surname><given-names>G.</given-names></name><name><surname>Castro</surname><given-names>A.</given-names></name></person-group><article-title>Activity of Melaleuca alternifolia (tea tree) oil on Influenza virus A/PR/8: Study on the mechanism of action</article-title><source>Antivir. Res.</source><year>2011</year><volume>89</volume><fpage>83</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2010.11.010</pub-id><pub-id pub-id-type="pmid">21095205</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="jcm-09-02441-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">jcm-09-02441-t001_Table 1</object-id><label>Table 1</label><caption><p>A panel of broad-spectrum antivirals in topical eye medications from the drug repurposing approach.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Original Indication</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Repurposing Potential as Antiviral</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Note</italic>
</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Benzalkonium Chloride (BAK) (0.015&#x02013;0.05%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preservative (Detergent)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., DNA (HSV-2, CMV, Adenovirus, BK Virus) and RNA (RSV, Enterovirus, Norovirus, Porcine Epidemic Diarrhea) Viruses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controversial Results for SARS-Cov-2 (See Text)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chlorobutanol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preservative (Detergent)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., HBV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sodium Perborate (And Related Hydrogen Peroxide)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preservative (Oxidative)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broad Antiviral Effect</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stabilized Oxychloro Complex (SOC) (Purite<sup>&#x000ae;</sup>, Bio-Cide International Inc., Norman, OK, USA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preservative (Oxidative)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broad Antiviral Effect</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Balancing Antimicrobial Efficacy and Toxicity of Currently Available Topical Ophthalmic Preservatives</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Methyl Paraben</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preservative (Chelating Agent)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiretroviral Effect</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Citric Acid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preservative (Chelating Agent)/<italic>Buffering Agent</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., Coxsackievirus, Herpesviruses, Porcine Epidemic Diarrhea Virus (Coronavirus)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thimerosal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preservative (Organomercurial)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., Pseudorabies Virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Removed from Ophthalmic Preparations for Toxic Effects</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Disodium-Ethylene Diamine Tetra-Acetate (EDTA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Buffering Agents</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., Porcine Epidemic Diarrhea Virus (Coronavirus)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phosphate-Buffered Saline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Buffering Agents</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., Porcine Epidemic Diarrhea Virus (Coronavirus)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sodium Bicarbonate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Buffering Agents</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., Calicivirus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Boric Acid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Buffering Agents</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., White Spot Syndrome Virus (WSSV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Povidone Iodine (&#x0003c;0.76% Free Iodine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiseptic Agent</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-Cov-2 and Others</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In Suspension Tests and Contact Times of 5 Min</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sodium Hypochlorite (At Least 0.21%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiseptic Agent</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., MHV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chlorhexidine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiseptic Agent</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., Coronaviruses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Modest Antiviral Action</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hexamidine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiseptic Agent</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., Coronaviruses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Weak Antiviral Action</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polyhexamethylene Biguanide (PHMB)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiseptic Agent</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., HIV, Herpesviruses, HPV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phenolic Compounds</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiseptic Agent</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broad Antiviral Effect</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Weak Antiviral Action</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High Molecular Weight Hyaluronic Acid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artificial Tear</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Coxsackievirus, Influenza Virus, HSV-1, Porcine Parvovirus (Coronavirus)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mild Inhibition Of HSV-1 and Porcine Parvovirus</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trehalose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artificial Tear</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., EMC Virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Carbopol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artificial Tear</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., HSV-1/HSV-2, HZV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lactoferrin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artificial Tear</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., HIV, CMV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chamomile Oils</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artificial Tear (<italic>Vegetal Extract</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., Herpesviruses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Echinacea Purpurea</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artificial Tears (<italic>Vegetal Extract</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., HSV-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Rubus Fruticosus (Blackberry)</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artificial Tears (<italic>Vegetal Extract</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., HSV-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Ginkgo Biloba</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artificial Tears (<italic>Vegetal Extract</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., Influenza A H3N2, HBV, Porcine Parvovirus (Coronavirus)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Centella Asiatica</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artificial Tears (<italic>Vegetal Extract</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., HSV-1, Vesicular Stomatitis Viruses (VSV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Foeniculum Vulgare</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artificial Tears (<italic>Vegetal Extract</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., Bluetongue Virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Aloe Vera</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artificial Tears (<italic>Vegetal Extract</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., SARS-CoV, CMV, Enterovirus 71, Japanese Encephalitis Virus, Herpesviruses, Influenza A Virus, Haemagglutinating Viruses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Aloe Emodin</italic> is an Anthraquinone and a Variety of Emodin Present in Aloe Latex, An Exudate From the Aloe Plant. In Some Cases, <italic>Aloe Emodin</italic> is Obtained and Studied After Extraction from the <italic>Isatis Indigotica</italic></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glycerol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artificial Tears (Excipient)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., HIV-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">L-Carnitine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artificial Tears (Excipient)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., HIV-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ozonated Oils</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artificial Tears (Excipients)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., Plant Viruses, Coronavirus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Presumed Antiviral Action on SARS-Cov-2 Based on Oxidation of Specific Viral Receptors in Cellular Plants</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zinc</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artificial Tears (Excipient)/Astringent Eye Drops</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-Cov-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blocking of Viral Replication by Inhibiting SARS-Cov-2 Polymerase Activity </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acetylcysteine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artificial Tears (Antioxidant)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., HIV-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vitamin A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artificial Tears (Antioxidant)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., Norovirus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vitamin C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artificial Tears (Antioxidant)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., Herpesviruses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vitamin D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artificial Tears (Immunomodulator)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., HCV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">By Improving Innate or Therapeutic Antiviral Response to Various Viruses</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chloroquine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artificial Tears (Immunomodulator)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-Cov-2, Retroviruses, Flaviviruses, And Coronaviruses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of the Ph Linked Steps of Viral Replication </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Timolol Maleate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-Glaucoma Eye Drops</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., HSV-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dorzolamide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-Glaucoma Eye Drops</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., Influenza Viruses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Brinzolamide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-Glaucoma Eye Drops</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., H3N2, H1N1, Avian H5N2, H7N1 Influenza Viruses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Azithromycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiotic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-Cov-2 Infection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tetracyclines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiotic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-Cov-2 Infection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluoroquinolones</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiotic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., Influenza Virus, Polyomavirus BK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aminoglycosides</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiotic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., Influenza A Virus, Japanese Encephalitis Virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chloramphenicol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiotic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., Herpetic Stomatitis, Herpes Labialis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colistin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiotic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., Mycobacteriophage D29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fusidic Acid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiotic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., HIV, JC Virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Itraconazole</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antifungal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., Parechovirus A3 (Picornaviridae), Influenza Virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Posaconazole</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antifungal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., ParechovirusA3 (Picornaviridae)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amphotericin B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antifungal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., Vesicular Stomatitis Virus, HSV-1, HSV-2, Sindbis Virus, Vaccinia Virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ketotifen Fumarate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-Allergic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., Dengue Virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controversial Results for Herpesviruses (See Text)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chlorcyclizine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-Allergic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., HCV, Filoviridae (Ebola Virus, Marburg Virus and Cuevavirus)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chlorpheniramine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-Allergic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., Influenza A Virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diphenhydramine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-Allergic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., Filoviridae (Ebola Virus, Marburg Virus and Cuevavirus)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flavonoids</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-Allergic/Artificial Tear</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., HSV-1, Polio-Virus Type 1, Respiratory Syncytial Virus (RSV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broad Effect on Eye Disease (See Text)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cyclosporine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-Allergic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., HCV, Flavivirus, Influenza Virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broad Effect on Inflammatory Eye Disease (See Text)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Indometacin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., HSV-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bromfenac</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., HSV-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr></tbody></table><table-wrap-foot><fn><p>Different types of active ingredients and excipients commonly contained in ophthalmic preparations that show antiviral side effects against various viruses (in addition to their primary use). These substances can have a broad-spectrum action, possibly including inhibition of replication/diffusion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the ocular surface. Abbreviations were as follows: Herpes simplex virus (HSV); Herpes simplex virus type 1 and/or 2 (HSV-1 and/or HSV-2); Herpes zoster virus (HZV); Cytomegalovirus (CMV); Hepatitis B virus (HBV); Hepatitis C virus (HCV); Human immunodeficiency virus (HIV); Human papillomavirus (HPV); BK virus: this infectious agent is a member of the polyomavirus family (it was first isolated in 1971 from the urine of a kidney transplant patient; initials B.K.); John Cunningham virus (JC virus or Human polyomavirus 2); Mycobacteriophage D29: this infectious agent is a Cluster A mycobacteriophage, belonging to the <italic>Siphoviridae</italic> family of viruses (notable for its ability to infect <italic>M. tuberculosis</italic>); Mouse hepatitis virus (MHV); Encephalomyocarditis virus (EMC).H<sub>(X)</sub>N<sub>(Y)</sub>: Influenza A viruses. Based on two proteins on the virus surface, i.e., hemagglutinin (H) and neuraminidase (N), these infectious agents are classified into different subtypes: H1N1 (the common cause of human influenza and generally associated with the Spanish flu), H3N2 (commonly associated with swine flu or seasonal H3N2 flu), H5N2 or H7N1 (generally associated with avian influenza virus or bird flu virus). e.g., -exempli gratia.</p></fn></table-wrap-foot></table-wrap></floats-group></article>